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Abstract
Huntington’s disease (HD) is an autosomally dominant, progressive movement disorder, 
caused by an expansion in the polyglutamine tract of huntingtin protein. HD is 
pathologically characterised by the presence of insoluble, proteinaceous neuronal 
intranuclear inclusions (NHs) and dystrophic neurite inclusions (DNls) in affected 
neurons that can be immunostained for ubiquitin and other proteins involved in the 
ubiquitin-proteasome system (UPS). The UPS is a highly conserved mechanism for 
degradation of both normal and misfolded proteins in eukaryotic cells. This has led to 
suggestions that the UPS is inhibited in HD. This study utilises microscopy, biochemistry 
and fluorometric assays to examine the molecular composition of aggregates and the 
potential dysfunction of the UPS in the R6/2 mouse line, an established model of HD. 
The ultrastructure of aggregates is shown to be predominantly amorphous and granular in 
appearance and likely to be formed through the process of transglutam ination. 
Immunohistochemical data shows that certain chaperones, ubiquitin-like proteins (UBLs) 
and proteins involved in the UPS localise to Nils and DNIs differentially. Fluorometric 
assays demonstrate that the proteasome exhibits a differential profile in R6/2 mice where 
both chymotrypsin-like and PGPH-like activities are markedly increased whilst trypsin­
like activity is decreased relative to litter-mate control mice. Furthermore, these activity 
changes may be explained by alterations in proteasome regulation, levels and maturation. 
These results suggest that, in the R6/2 line, the proteasome is not inhibited by the 
presence of mutant huntingtin, rather that there are alterations of the catalytic activities of 
the proteasome. It appears that N il’s act not only as focal points of proteolysis, but also 
of proteasome biogenesis. This is consistent with, and extends, the concept of 
clastosomes.
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CHAPTER 1
Introduction
1.1 Introduction to Huntington’s disease
H unting ton’s disease (HD) is a p rogressive, au tosom ally  dom inant 
neurodegenerative disease that was named after the Long Island physician, George 
Huntington, who provided the first accurate description of this illness. In his 
seminal paper “On Chorea”, published in 1872 in the Philadelphia based journal 
The Medical & Surgical Reporter, Huntington made key observations regarding 
the age of onset, psychiatric disturbances and hereditary nature of this disease, 
which are still considered to be definitive features of the disease.
HD is clinically characterised by psychiatric abnormalities, hyperkinesia, and 
cognitive decline. The psychiatric abnormalities can include hypersexuality, 
suicidal tendencies, depression or anti-social behaviour. These behavioural changes 
appear before the involuntary writhing, chorea-form movements, which are 
characteristic of the disease. HD patients can, but do not always, experience 
cognitive decline to varying degrees (Nance, 1998). The juvenile variant of HD, 
which accounts for approximately 1-7% of HD cases presents differently with 
symptoms that are more parkinsonian in nature (such as bradykinesia, rigidity and 
tremor) and with slightly less cognitive impairment than the adult onset variant
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(Gomez-Tortosa et al., 1998; Rasmussen et al., 2000; Nance and Myers, 2001; 
Seneca et al., 2004).
Typically, HD will present in the fourth or fifth decade, although there are several 
known modulators of the age of onset (see 1.1.2). The typical time course from 
disease onset to death is 15-25 years. Juvenile HD, defined as presenting before 20 
years of age, can occur as early as 2 years of age and typically results in a shorter 
disease time course (Foroud et al., 1999).
1.1.1 Neuropathology in Huntington’s disease
The neuropathological changes in HD are quite striking. HD brains weigh ~30% 
less than age-matched control (de la Monte et al., 1988), with reduction in the size 
of most regions of the brain. There is thinning of the cerebral cortex and severe 
atrophy of areas of the striatum (particularly the caudate nucleus and putamen), 
which is accompanied by a consequent enlargement of the lateral ventricle. All of 
these features are visible macroscopically (de la Monte et al., 1988; Rosas et al., 
2003) (Figure 1).
There are numerous quantitative studies detailing the extent of neuronal loss from 
the striatum and cortex, some of which also indicate marked astrocytosis and 
microglial activation (Hedreen et al., 1991; Myers et al., 1991; Hedreen and 
Folstein,1995; Pavese et al., 2006). Although there is severe degeneration in the
13
Control
Figure 1: Neuropathology in Huntington’s disease brains. Gross neuronal atrophy is 
macroscopically visible in coronally sectioned cerebral hemispheres in an HD brain (right) 
when compared to an age-matched control (left). Particularly evident is the enlarged ventricle 
(Vt), thinned caudate nucleus (Cd) and atrophied putamen (Put). Photograph taken from  
(Gutekunst et al., 2002)
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HD striatum, the pattern of neuronal loss is far from uniform. In early stage HD, there 
appears to be a preferential loss of three types of strial projection neurons (those that 
project to the globus pallidus external segment, substantia nigra pars reticulata and 
substantia nigra pars compacta) which is accompanied by a much more gradual loss of 
globus pallidus internal segment-projecting neurons. However, in late stage HD, all 
four populations are reduced (Deng et al., 2004). In addition, virtually all striatal 
chemospecific interneurons (those that contain calretinin, NADPH, parvalbumin, 
calbindin or ChAT) are spared in HD, thus leading to their increased density 
throughout the course of the disease (Cicchetti et al., 2000).
Using Golgi impregnations to visualise the dendritic morphology of spiny striatal 
neurons, both proliferative and degenerative changes have been described. In moderate 
grades of HD, the proliferative changes dominate (dendritic curving, branching and 
increased spine numbers), whereas in severe grades of HD, the degenerative changes 
predominate, such as truncated dendritic arbors, dendritic swellings and significant 
loss of spines (Graveland et al., 1985; Ferrante et al., 1991).
A grading system exists to classify the severity of the neuropathology in HD, ranging 
from 0-4, with 4 being classed as the most severe grade. This scale was devised using 
both macroscopic and microscopic criteria from post-mortem tissue of 163 clinically 
diagnosed HD cases and correlates well with the clinical manifestations of the disease. 
Grade 0 cases, although clinically diagnosable with HD, do not show any gross or 
microscopic pathology, demonstrating that detectable anatomical changes follow
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behavioural disorders. Grade 1 cases show moderate astrocytosis and up to 50% 
neuronal loss in the caudate nucleus. Grades 2-4 show increasing astrocytosis, 
enlargement of the lateral ventricle and severe neuronal loss in the caudate nucleus (as 
much as 95%) and putamen (Vonsattel et al., 1985).
HD is characterised by the presence of insoluble protein aggregates in both the nucleus 
and neurites of affected neurons. These have become one of the defining pathological 
features of HD and are described later in detail (see 1.1.5).
1.1.2 Genetics of Huntington’s disease
The prevalence of HD worldwide varies considerably with area - some areas have high 
occurrences (Venezuela) and in some areas HD is almost none existent (eg. Finland, 
Japan). Epidemiological studies show variance in the prevalence of HD in European 
populations, but most figures seem to fall within the region of 4-8 per 100,000 
(Harper, 1992).
In 1993, the Huntington’s Disease Collaborative Research Group mapped the gene 
responsible for HD to a region on chromosome 4 (4pl6.3), named IT15 (“interesting 
transcript 15”). This gene, spanning 67 exons, encoded a large protein of unknown 
function, which was subsequently named huntingtin. In HD, there is an expansion of 
the trinucleotide CAG repeat sequence (which codes for glutamine) found in exon 1 of
16
IT 15 (Huntington's Disease Collaborative Research Group, 1993). Polyglutamine tract 
lengths in huntingtin protein are polymorphic and in normal populations are typically 
between 14-26 glutamines; tracts between 27-35 repeats are not associated with HD 
(but may expand in paternal / maternal transmission); individuals with tracts between 
36-39 repeats display reduced penetrance -  ie. a proportion of individuals develop HD. 
However, 40 polyglutamine repeats appears to be the threshold for disease -  any 
higher numbers of CAG repeats, and HD will present (Myers, 2004).
There is an inverse correlation between the length of the polyglutamine tract and the 
age of onset; large repeats of 60 or more typically result in juvenile onset HD (Gusella 
and MacDonald, 2000; Wexler et al., 2004). Juvenile HD cases with polyglutamine 
repeat lengths as high as 214 have been reported (Seneca et al., 2004). But, whilst 
there exists a significant correlation between polyglutamine tract length and age of 
onset of disease, the repeat length only accounts for 65-71% of the variance in the age 
of onset (Rosenblatt et al., 2001; Wexler et al., 2004). Epidemiological studies have 
shown that the variation in age of onset that is not attributable to repeat size, is due to 
genetic modifiers in 40-56% of cases and environmental causes in 44-60% of cases 
(Djousse et al., 2003; Wexler et al., 2004). It has been shown that approximately 1% of 
the variance in age of onset is due to the repeat length in the normal allele; suprisingly, 
the longer the repeat length in the normal allele, the later the age of onset (Djousse et 
al., 2003).
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Patients that are homozygous for the HD gene do not differ clinically from 
heterozygous patients, in terms of severity or course of the disease, demonstrating that 
HD is a completely phenotypically dominant disorder (Wexler et al., 1987).
1.1.3 Huntingtin
Huntingtin is a large 348 kDa protein consisting of 3,144 amino acids (Huntington’s 
Disease Collaborative Research Group, 1993) and shares little sequence homology 
with other known proteins. However, huntingtin does contain three prominent motifs: 
a polyglutamine tract after the first 18 amino acids, which is immediately followed by 
a polyproline tract and 10 HEAT (htt, elongation factor 3, the regulatory A subunit of 
protein phosphatase 2A and TO RI) repeats, which are clustered into three domains in 
the N-terminal region of the protein. Polyglutamine / polyproline tracts are thought to 
be involved in transcription and HEAT repeats have been suggested to play a role in 
transport, microtubule dynamics and chromosome separation (Harjes and Wanker, 
2003).
Although expressed ubiquitously in humans and rodents, huntingtin is particularly 
highly expressed in the brain and testes, with no obvious pattern of expression that 
mirrors the pathology seen in HD. Subcellularly, Huntingtin is found with the 
cytoskeleton, in the cytoplasm associated with a variety of organelles, such as the golgi
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complex, vesicle membranes, and has even been shown to localise to the nucleus (Li et 
al., 1993; DiFiglia et al., 1995; Sharp et al., 1995; Jeong et al., 2006).
The details of huntingtin’s cellular functions have remained elusive. In spite of this, 
several proteins have been found that associate with huntingtin (mainly through the N- 
terminal portion) and they can largely be grouped into proteins that are either involved 
in transcription (eg.TBP), trafficking and endocytosis (eg. HAP1), signalling (eg. 
Grb2) or metabolism (eg. HIP2) (Li and Li, 2004). To date, roles in various cellular 
functions have been suggested, such as modulation of dendritic morphology, 
transcriptional regulation, cellular transport and survival (Harjes and Wanker, 2003; 
Cattaneo et al., 2005). Several groups have shown that homozygous disruption of the 
mouse huntingtin gene results in embryonic lethality, thus highlighting the importance 
of huntingtin in development (Duyao et al., 1995; Zeitlin et al., 1995). The fact that 
mice expressing huntingtin with expanded (M angiarini et al., 1996) or deleted 
polyglutamine stretches (Clabough and Zeitlin, 2006) are viable, demonstrate that this 
portion of the protein is not essential for development.
Interestingly, a condition called Wolf-Hirschhorn Syndrome (WHS), which is caused 
by a hemizygous deletion of the distal short arm of chromosome 4, has a disease 
phenotype (facial dysmorphia and mental / growth retardation) completely distinct 
from that of HD, which demonstrates that HD is not caused simply by a loss of 
huntingtin activity (Gandelman et al., 1992). A recent study found that one of the 
functions of huntingtin was to regulate body weight, with overexpression causing
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weight gain (Van Raamsdonk et al., 2006). As one of the features of HD is an 
increasing loss of body weight, often despite a high calorific intake, it is possible that 
some of the features of HD could be as a result of loss of normal huntingtin function.
1.1.4 Polyglutamine expansion diseases
HD is one of a family of polyglutam ine expansion diseases, which includes 
dentatorubropallidoluysian atrophy (DRPLA), spinal and bulbar muscular atrophy 
(SBMA) and various spinocerebellar ataxias (SCA’s). To date, nine polyglutamine 
expansion diseases have been identified (Figure 2). Importantly, in all of these diseases 
the expanded polyglutamine stretch is present in seemingly unrelated proteins, yet they 
exhibit striking similarities -  an autosomal dominant pattern of inheritance (except 
SBMA, which is X-linked), the presence of neuronal intranuclear inclusions (see 
chapter 1.1.5), the relationship of repeat length to age of onset / severity of disease and 
a progressive nature to neurological dysfunction (Ordway et al., 1997). Another feature 
of HD and indeed all polyglutamine expansion diseases, is that they exhibit a feature 
called anticipation. Anticipation is defined as the tendency for inherited disorders to 
present at an earlier age in successive generations, often with increasing severity. In 
the case of polyglutamine disorders, this is usually brought about by a continued 
expansion of the polyglutamine tract in successive generations, although much less 
common and smaller polyglutamine contractions have also been reported (La Spada et 
al., 1994).
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Disease Name(s)
Protein
containing
polyQ
expansion
Function of normal 
protein
Primary sites of 
neuropathology
Normal
polyQ
lengths
Reported
disease
allele
lengths
HD
(Huntington’s disease) Huntingtin Unknown CN, PU, GPe 6-35 36-121
DRPLA 
(Dentatorubro-pall idoluysian 
atrophy) or Haw river syndrome
Atrophin-1 Transcriptional co­repressor
CE (DN), RN, GPe, 
STN 3-35 49-88
SBMA 
(Spinal & bulbar muscular 
atrophy) 
or Kennedy’s disease
Androgen
receptor Steroid receptor AHC 11-38 38-62
SCA-1 
(Spinocerebellar ataxia-1) Ataxin 1
Regulatory factor in 
gene expression?
CE (PC & DN), 
RN, 10, pons, AHC, 
pyramidal tracts
6-44 40-81
SCA-2 Ataxin 2 Unknown CE (PC), IO, pons, SNpc, AHC 15-29 35-59
SCA-3
or Machado-Joseph Disease 
(MJD)
Ataxin 3 Involved in de- 
ubiquitination??
CE (monolayer 
cells), pons, SNpc, 
SNpr, AHC
12-41 55-84
SCA-6
Isoform o f  aiA 
Ca2+ channel 
subunit
Calcium channel 
subunit CE (PC, MG) 4-17 20-30
SCA-7 Ataxin 7 Histone
acteylation??
CE (PC, MG), pons, 
IO, AHC, retina 4-35 37-220
SCA-17 TATA-bindingprotein Transcription factor
CE (PC), CA, PU, 
thalamus 29-42 47-55
Figure 2: Currently identified polyglutamine expansion diseases. Table demonstrating that 
polyglutamine expansion diseases occur in proteins with seemingly unrelated function. The 
threshold of polyglutamine tract length resulting in disease is fairly similar between diseases 
and has been reported to be as high as 220 repeats in SCA-7. The regions of neuropathology 
(atrophy, cell death etc) in these diseases also greatly varies, highlighting the role that the 
disease protein plays in the selective vulnerability of neurons. AHC=Anterior horn cells; 
CA=Caudate; CE=Cerebellum; CN=Caudate nucleus; DN=Dentate nucleus; GPe=Globus 
pallidus, external segment; IO=Inferior olive; MG=Molecular & granular layers; 
PC=Purkinjee cells; PU=Putamen; RN=Red nucleus; SNpc=Substantia nigra pars compacta; 
SNpr= Substantia nigra pars reticulata; STN=Sub-thalamic nucleus. Adapted and compiled 
from several sources (Gusella and MacDonald, 2000; Nakamura et al., 2001; Zhang et al., 
2002; Rudnicki and Margolis, 2003; Scheel et al., 2003; Tarlac and Storey, 2003; van Roon- 
Mom et al., 2005).
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The common features in these disorders imply that a polyglutamine expansion above a 
certain threshold confers a gain of function on a protein, regardless of its normal 
cellular function. It has been shown that insertion of a 146 CAG repeat stretch into 
exon 3 of murine hypoxanthine phosphoribosyltransferase (HPRT), a protein unrelated 
to identified repeat expansion diseases, results in a delayed onset, progressive 
neurological phenotype, accompanied by neuronal intranuclear inclusions (Ordway et 
al., 1997). This rather eloquently demonstrates that polyglutamine expansion causes 
neurological dysfunction regardless of the context of the protein which it lies in. 
Certainly, the context of the protein may have an effect on the nuances between these 
diseases -  region of affected neurons (Figure 2), disruption of normal function of 
protein etc. For example, in SBMA, the polyglutamine expansion lies within the 
androgen receptor (AR) and accom panying motor dysfunction are a range of 
testosterone-related dysfunctions -  muscle wasting, gynecomastia and testicular 
atrophy.
1.1.5 Protein aggregation in HD and other polyglutamine expansion diseases
One of the pathological hallmarks of HD is the presence of insoluble, proteinaceous 
aggregates present in both the nucleus and neurites of affected neurons in the cortex 
and striatum, termed neuronal intranuclear inclusions (Nils) and dystrophic neurite 
inclusions (DNIs), respectively (Davies et al., 1997; DiFiglia et al., 1997). N ils and 
DNIs can be visualised at the electron microscopic level -  in fact nuclear inclusions
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were first noted in studies on HD tissue as early as 1979 (Roizin et al., 1979). 
Typically, Nils are non membrane-bound circular structures that have a pale, granular 
appearance at the ultrastructural level, are on average 1.65 (±0.05) pm in diameter and 
occupy approximately 10-20% of the nuclear area (Davies et al., 1997). DNIs are also 
non membrane-bound structures that tend to be slightly ovoid in shape with a length of 
between 3.5-12pm. In adult-onset HD, DNIs are much more frequent than N il’s, and 
in juvenile-onset HD, this trend is reversed (DiFiglia et al., 1997). These inclusions 
can be visualised by immunohistochemical staining using antibodies raised against 
either huntingtin or ubiquitin (see 1.2.1). However, analysis of both HD brains and a 
transgenic mouse model of HD (see 1.1.7) has shown that DNIs and Nils can only be 
detected with antibodies raised against the N-terminal portion (and not C-terminal) of 
huntingtin, suggesting that inclusions are made up of N-terminal fragments (DiFiglia 
et al., 1997; Sieradzan et al., 1999). Further evidence comes from the work of Lunkes 
et al., who used a panel of antibodies against huntingtin to ascertain what length of 
huntingtin fragments were present in inclusions in HD brains. They showed that Nils 
are primarily made up of N-terminal fragments of huntingtin and that whilst the DNIs 
are also made up of N-terminal fragments, some were slightly larger than those found 
in Nils (Lunkes et al., 2002). In spite of this, C-terminal huntingtin antibodies still 
have not been shown to label inclusions in HD (Stephen Davies, UCL, UK, personal 
communication).
It has been suggested that some of the cellular dysfunction in HD results from proteins 
which are sequestered into aggregates, therefore unable to perform their normal
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cellular functions. A wide variety of proteins have been shown to be recruited to 
polyglutamine inclusions including chaperones (see 1.3), proteasome components (see 
1.2) and transcription factors, such as TBP (van Roon-Mom et al., 2002) and CBP 
(McCampbell et al., 2000).
1.1.6 Mechanisms of protein aggregation in polyglutamine disorders
There are two main mechanisms which have been suggested to explain how expanded 
polyglutamine-containing proteins aggregate -  hydrogen bonding by polar zipper 
formation and covalent cross-linking by transglutamination.
In 1993, Howard Green postulated that transglutaminase, an enzyme expressed in 
brain and other tissues, catalyses the formation of specific isopeptide bonds (e-(y- 
glutamyl) lysine crosslinks) between glutamine and lysine residue in side chains of 
adjacent proteins (Green, 1993). Huntingtin has been shown to be a substrate of 
transgluaminase in vitro and additionally, that longer polyglutamine stretches produce 
polymers at a higher rate (Kahlem et al., 1998). One study showed that 
transglutaminase selectively co-immunoprecipitates and localises with truncated, but 
not full length huntingtin, and that it modifies proteins associated with huntingtin, but 
not huntingtin itself. The authors suggest that after proteolytic processing of 
huntingtin, transglutaminase may be involved in aggregation (Chun et al., 2001). The 
link between short huntingtin fragments and increased in vitro aggregation caused by
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transglutaminase (when compared to larger fragments) has also been demonstrated 
(Karpuj et al., 1999). Whilst there is limited evidence to suggest that aggregates in HD 
brains are caused by transglutamination, studies have shown that there is an increase in 
transglutaminase in HD brains (Karpuj et al., 1999; Lesort et al., 1999) and that HD 
cerebrospinal fluid has a 3-fold increase in s-(y-glutamyl) lysine (Jeitner et al., 2001).
In 1994, based on the properties of a synthesized polyglutamine containing peptide, 
Max Perutz suggested that glutamine repeats could function as “polar zippers”, by 
hydrogen bonding main chain and side chain amides to form tightly linked P-sheets 
(Perutz et al., 1994). However, support for this method of aggregation is far from 
conclusive and often conflicting. In one study, purified GST-fused huntingtin proteins 
containing a variety of disease-length polyglutam ine tracts (51, 83 and 122 
glutamines), but not proteins containing shorter polyglutamine tracts (20 and 30 
glutamines), were found to aggregate in vitro, but only after proteolytic cleavage of the 
GST domain. As purified proteins were used in these preparations and electron 
microscopic analysis showed the presence of fibrils, the authors concluded that 
huntingtin aggregates are likely to form amyloid-like structures in vivo (Scherzinger et 
al., 1997). A problem with this theory is that small 10 glutamine tract proteins have 
also been shown to oligomerize in vitro (Stott et al., 1995), yet polymerized huntingtin 
aggregates are not detected in the normal population (ie. huntingtin with tracts of 35 
glutamines or less). In HD post-mortem tissue, Congo red (an amyloidophilic stain) 
stained green birefringent inclusions have been detected, although in smaller numbers 
than ubiquitin-positive inclusions (Huang et al., 1998; McGowan et al., 2000),
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showing that this may occur in polyglutamine diseases, but may not be the main 
mechanism for aggregation. However, another study failed to Congo red stain any 
inclusions in HD post-mortem tissue (Karpuj et al., 1999). A relatively recent paper 
described several species of mutant huntingtin-GST structures (including spherical, 
annular, amorphous and fibrillar) with both spherical and annular structure formation 
attenuated by Hsp70 and Hsp40; the authors concluded proposed two models of fibril 
formation. In one, pathways that encourage spherical, annular and amorphous 
structures essentially competed with pathways that promoted fibril formation. In the 
other, spherical oligomers were prerequisites to fibril formation and annular and 
amorphous were metastable by-products that compete with pathways promoting fibril 
formation (Wacker et al., 2004). However, these experiments were performed in vitro 
and it remains to be seen whether these structures form in vivo.
It remains to be seen whether either of these hypotheses regarding polyglutamine 
aggregation turn out to be correct. W hat is clear, however, is that proteins with 
expanded polyglutamine stretches adopt novel conformations which result in protein 
aggregation. Typically, the fate of misfolded proteins in a cell may go down two 
possible routes: either corrective folding, for example through the actions of 
chaperones (see 1.3), or degradation, the main mechanism of which being the 
ubiquitin-proteasome system (see 1.2).
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1.1.7 The R6/2 model of HD
The identification of the relevant genes in HD and other polyglutamine disorders 
prompted the generation of several murine models, which serve to act as powerful 
tools for investigating the neurobiology of these diseases. Although several murine 
models of HD exist, including various knock-in, YAC or BAC approaches, without 
doubt, the most established and well characterised murine model remains the R6/2 
model. This transgenic model was created by inserting a 2kb fragment encoding exon 
1 of human huntingtin protein, containing approximately ~145 polyglutamine repeats, 
and the human huntingtin promotor (Figure 3). This model exhibits a progressive 
neurological phenotype that recapitulates many of the features of HD, including resting 
tremor, movements akin to chorea and stereotypic involuntary movements. The onset 
of these motor disturbances is usually around 8-9 weeks of age, and death usually 
occurs from 13 weeks old onwards (Mangiarini et al., 1996). Depending on the tasks 
assessed, cognitive decline can be detected in the R6/2 mice as early as 3.5 weeks 
postnatally (Lione et al., 1999). Furthermore, R6/2 mice exhibit decreased body 
weight, with decreases of 30-40% when compared to litter-mate controls, and on a 
gross neuropathological level, R6/2 brains weigh 20% less (see Figure 4). Detailed 
neuropathological studies have been carried out on R6/2 brains with Nissl staining 
revealing no abnormal brain architecture, and GFAP (glial fibrillary acidic protein) and 
F4/80 immunohistochemistry revealing no reactive astrocytosis (Mangiarini et al., 
1996). Immunohistochemical analysis, using antibodies raised against either ubiquitin
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Figure 3: Construct of the transgene in the R6/2 line. R6/2 mice express exon 1 of human 
Huntingtin protein (under the control of the human Huntingtin promotor) with a polymorphic 
polyglutamine stretch of ~ 130-150 repeats. (Picture by L. J. Bannister, UCL; adapted from 
Mangiarini etal., 1996)
28
A 30
25
20s
2
I
f
00
2 6 8 10 12 1440
Age in Weeks
4 00  -
" . . .
£  360
Agp in weeks
Disease Progression in 6/2 HT Mice
PHENOTYPE
Brain Weight Loss 
Body Weight Loss 
Symptoms
NEUROPATHOLOGY 
htt in Nucleus 
Ubiquitin in Nucleus 
Nil by EM 
Nuclear Indentation
Age in Weeks 2
- - - + ++ ++ +++ +++ +++ +++ +++ +++
+ + + ++ +++ +++ +++
■ + + ++ ++ +++
_ + + + ++ ++ +++ +++ +++ +++ +++
+ + + + ++ +++ +++ +++
+/- + + ++ ++ ++ -H-
+ + + ++ ++
3 3.5 4 4.5 5 6 7 8 9 10 11 12 13
Figure 4: An overview of the phenotype and neuropathology in the R6/2 mouse. The
progressive decreases in (A) body and (B) brain weight correlates with (C) neuropathological 
changes in R6/2 mice. Initially huntingtin is present in the nucleus at ~4.5 weeks and is then 
ubiquitinated at 6 weeks. This immunohistochemical detection of Nils preceeds their detection 
by ultrastructural analysis. Dotted and continuous lines in (A) and (B) represent R6/2 and 
LMC mice, respectively. Taken from Davies etal. (1997).
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or the N-terminus of Huntingtin, detected the presence of Nils (Davies et al., 1997) 
and DNIs (DiFiglia et al., 1997) in R6/2 brains as early as 4 weeks of age, which 
preceeds the motor symptoms. It is worth mentioning that although retrospective 
literature searches reveal that Nils were noted in ultrastructural studies in HD brains as 
early as 1979 (Roizin et al., 1979), it was their identification in R6/2 brains that led to 
their subsequent detection and status as a pathological hallmark of HD in human tissue 
(DiFiglia et al., 1997). This emphasises the relevance of this model in producing 
findings that relate to polyglutamine disease in humans. Additionally, in a recent 
publication studying the chronology of behavioural and neuropathological changes in 
R6/2 mice (Figure 4), the authors concluded that this model very closely resembles 
many key aspects of human HD (Stack et al., 2005).
1.2 The Ubiquitin-Proteasome System (UPS)
The levels of proteins in a cell are dictated by the rates of protein synthesis and 
degradation. The main methods of protein degradation in a cell are either lysosomal 
degradation, macroautophagy or via the ubiquitin-proteasome system. Whilst there is 
evidence to suggest that both lysosomal degradation and macroautophagy have roles in 
the clearance of misfolded proteins in neurodegenerative disease (Qin et al., 2003; 
Ravikumar et al., 2005), this thesis is concerned with the role of the UPS in HD.
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The UPS is a highly conserved mechanism of degradation of both normal and 
misfolded proteins in eukaryotic cells. The proteasome complex is thought to consitute 
as much as 1% of eukaryotic cellular protein (Hershko and Ciechanover, 1998). It has 
been suggested that 80-90% of cellular protein degradation is attributable to the 
proteasome, with the lysosome responsible for the remainder (Rock et al., 1994). 
Components of the ubiquitin-proteasome system have been implicated in cellular 
functions as diverse as regulation of translation, activation of transcription factors (eg. 
NF-kB) and kinases, cell-cycle control, DNA repair, endosomal transport and labelling 
of membrane proteins for degradation in lysosomes (Weissman, 2001; Klimaschewski,
2003). With such a variety of important cellular functions it is, perhaps, not surprising 
that this system has been im plicated in human disorders from  cancer to 
neurodegenerative disease.
In eukaryotic cells, proteasomes are found distributed in both the nucleus and 
cytoplasm, although the levels in either compartment vary with cell type. In the 
cytoplasm, proteasomes are typically concentrated on the surface of the endoplasmic 
reticulum and cytoskeletal networks and in the nucleus proteasomes are found 
distributed throughout the nucleoplasm (excluding the nucleolus), occasionally 
forming multiple focal points once again, depending on cell type. Generally, in CNS 
neurons, immunostaining with antibodies against proteasome subunits seems to label 
nuclei much more intensely than the cytoplasm (Wojcik and DeMartino, 2003). 
However, certain proteasome subunits are expressed at very low levels in the brain, 
such as immunoproteasome subunits and l i s p  (see 1.2.2)(Rechsteiner et al., 2000),
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which effectively can alter the “type”, and therefore proteolytic profile (see 1.2.4), of 
proteasomes present in differing tissues (Noda et al., 2000).
1.2.1 An overview of the ubiquitin proteasome pathway
Unlike proteases compartmentalized in lysosomes, the proteasome is widespread 
throughout the cell and, as such, requires a highly specific and regulated mechanism of 
selecting proteins for degradation. This is achieved by “tagging” target proteins with 
polyubiquitin chains which are subsequently recognised by the proteasome and then 
degraded. Ubiquitin is a small 8.6 kDa protein that covalently binds to lysine residues 
on target proteins via an enzymatic cascade. Initially, a ubiquitin-activating enzyme 
(E l) binds ubiquitin in an ATP-dependent manner. The ubiquitin molecule is then 
transferred to a ubiquitin conjugating enzyme (E2) which subsequently catalyses its 
transfer to the ubiquitin-ligating enzyme (E3)-bound target protein. Based upon the 
presence of certain motifs, E3 enzymes can be classed as HECT (Homologous to the 
E6-AP Carboxyl Terminus) or RING finger ligases. RING finger ligases catalyse the 
transfer of ubiquitin directly from the E2 enzyme to the substrate, whilst HECT E3 
ligases bind ubiquitin from E2 enzymes and then transfer it to the substrate. Through 
sequential addition of further ubiqutin molecules a polyubiquitin chain is generated. 
Lys-48 polyubiquitinated proteins (see below) are then targeted and recognised by the 
proteasome and degraded into sm aller peptides. Additionally, deubiquitinating 
enzymes coordinate with this process to remove ubiquitin molecules for recycling
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(Figure 5) (Weissman, 2001; Ciechanover and Brundin, 2003). It should mentioned at 
this point that there are several types of polyubiquitin chain; there are several lysine 
residues in the ubiquitin protein (Lys-6, Lys-11, Lys-27, Lys-29, Lys-33, Lys-48, or 
Lys-63) and the function of polyubiquitin chains are different depending on which 
ubiquitin lysine residue the Gly-76 of subsequent ubiquitins in the chain binds to 
(Voges et al., 1999). For example, whilst Lys-48 polyubiquitinated chains are known 
to signal proteasomal degradation, Lys-11 polyubiquitin residues have also been 
shown to signal proteasomal degradation but only in vitro and Lys-63 chains can 
signal several pathways, including protein trafficking and autophagy (Pickart & 
Fushman, 2004; Tan et al., 2007).
1.2.2 Structure of the Proteasome
The central component of the UPS is a multisubunit proteolytic complex referred to as 
the 20s core particle. The 20s complex is made up of four stacked heptameric rings 
which form a cylindrical shape with a central “pore” channel. The identical two outer 
rings are each composed of seven a-subunits ( a 17), whilst the identical inner two rings 
are each made up of seven |3-subunits (|3j .7) (Figure 6)(Bochtler et al., 1999). There are 
three main proteolytic activities of the mammalian 20s core particle: chymotrypsin- 
like, trypsin-like and peptidylglutamyl peptide hydrolysing (PGPH or caspase-like)
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Figure 5: An overview of the Ubiquitin-Proteasome System. Schematic illustrating the 
process of ubiquitination and subsequent degration of proteins. Ubiquitin is first activated by 
El enzymes and then transferred to E2 enzymes. E3 enzymes then catalyse the transfer of 
ubiqutin either directly (in the case of RING finger E3s) or indirectly (in the case of HECT 
domain E3s) to the bound substrate (S). After multiple cycles of ubiquitination, a polyubiquitin 
chain is generated signalling the degradation of the substrate by the proteasome into small 
peptides and the recycling of ubiquitin molecules via deubiquination. Adapted from Weissman 
(2001) and Ciechanover & Brundin (2003).
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Figure 6: An overview of proteasome structures and variations. 20s core particles are 
composed of 2 outer heptameric a-rings and 2 inner heptameric firings. Upon y-interferon 
stimulation, immunoproteasomes are formed, where the catalytic subunits p i , P2 and P5 are 
replaced by p li, P2i and P5i. Both 19s and l l s  regulatory complexes can bind (alone or in 
combination) to the a-ring of the 20s core particle to activate and alter the proteolytic profile 
of the proteasome. Adapted from Ferrell et al. (2000) and Cascio et al. (2002).
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which cleave after hydrophobic, basic and acidic amino acids, respectively (Orlowski 
and Wilk, 2000). Proteolysis actually takes place well within the 20s pore and the three 
main peptidase activities of the proteasome can be localised to specific subunits -  
chymotrypsin-like activity to p r subunits, trypsin-like activity to (32-subunits anc* 
PGPH activity to p5-subunits (Bochtler et al., 1999).
The pore of the 20s proteasome is almost closed by the tight a-ring , preventing 
proteins from accessing the proteolytic sites within the channel and essentially 
maintaining 20s proteasomes in a latent state (Baumeister et al., 1998). Several protein 
complexes have been demonstrated to bind to the 20s complex, the principal ones 
being the 19s and l l s  complexes, both of which serve to open the pore. These 
complexes can bind to either end of the 20s proteasome via interactions with the a -  
ring and alter the proteolytic profile of the proteasome (see 1.2.4).
The 19s regulatory complex (also known as PA700) associates with the proteasome in 
an ATP-dependent manner. It is comprised of two subcomplexes -  the base and the lid 
(Glickman et al., 1998). The base is composed of 6 ATPase (Rptl-6)* and 3 non- 
ATPase (Rpnl, 2 & 10) subunits and opens the proteasomal pore when it binds to the 
20s a-ring (Ferrell et al., 2000)(Figure 6). Additionally, the base subcomplex has been 
shown to have chaperone-like activity in vitro and may serve to unfold the targeted 
protein and translocate it into the pore (Braun et al., 1999). The lid is comprised of 8 
non-ATPase subunits (Rpn 3, 5, 6, 7, 8, 9, 11 & 12) and is necessary for 
deubiquitination (Ferrell et al., 2000). Specific functions have been mapped to
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individual subunits within the proteasome. For example, RpnlO contains polyubiquitin 
binding sites and is thought to target polubiquitinated substrates to the proteasome 
(Young et al., 1998) as does Rpt5 (Lam et al., 2002). Additionally, the lid subunit, 
R p n ll ,  is thought to be responsible for deubiquitination of polyubiquitinated 
substrates (Verma et al., 2002).
* - The proteasome subunits are here referred to by their well-known yeast 
nomenclature to avoid confusion. However, the mammalian nomenclature can be 
found in the appendix.
The l l s  regulatory complex (also known as PA28 or llsR E G ) is a heptameric ring 
that binds to the 20s a-subunits in a similar manner to the 19s complex. The l l s  
complex is heteromeric, comprised of two distinct subunits (sharing ~50% homology) 
termed 1 Is a  and 1 IsP (Ahn et al., 1995). Another protein sharing significant sequence 
homology with 1 ls a /p , has also been shown to activate the proteasome and was 
subsequently named llsy . llsy  is thought to form homomeric rings (Realini et al., 
1997; Tanahashi et al., 1997). l i s a  and p, and to a lesser extent llsy , have been 
shown to be induced by interferon-y (IFN-y) (Rechsteiner et al., 2000).
Various types of proteasomes can be visualised by incubation of proteasome 
complexes and subsequent visualisation by negative staining electron microscopy. 
This in vitro method reveals the possible existence of several different species of 
proteasome -  20s proteasome, singly-capped (19s-20s) and doubly-capped (19s-20s-
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19s) proteasomes with 19S complexes, singly-capped (lls-2 0 s) and doubly-capped 
(lls-20s-PA28) proteasomes with l l s  complexes as well as a hybrid proteasome with 
a l l s  and 19s complex bound to either end (19s-20s-lls)(Figure 6) (Cascio et al., 
2002).
Additional variations of proteasomes can be achieved as three different 20s subunits 
have been shown to be induced by IFN-y. In this situation, the three catalytically active 
subunits (p i, (32 & (33) are substituted by three “immuno” subunits - p li (also known 
as LMP2), P2i (also known as MECL-1) and |35i (also known as LMP7) -  which 
serves to alter the proteolytic profile of the proteasome, by forming de novo 
“immunoproteasomes” (1.2.4; Figure 6).
1.2.3 Proteasome assembly
Much of the work on early stage proteasome assembly comes from archaebacterium 
and considerably less data comes from mammalian cells. Many of the (3-subunits ((31, 
(32, |35, |36 & (37) exist as precursors that undergo limited proteolysis of the propeptide 
to reveal their active sites during biogenesis. It is thought that the formation of the a -  
ring is one of the earliest events in 20s proteasome biogenesis, a-rings have been 
shown to self-assemble using recombinant a-7  to “seed” ring formation (Gerards et al., 
1998). Based on studies immunoprecipitating early intermediate stage mouse 
proteasomes, the a-ring is then bound to (32, (33 and (34 subunits (Nandi et al., 1997).
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Subsequent addition of the remaining |3-subunits and the binding of proteasome 
maturation protein (POMP) is required before half-proteasomes dimerize to form a 
short-lived, inactive but complete “preholoproteasome”. This is thought to interact 
with the chaperone Hsc70 and concomitantly, propeptide sequences are autolytically 
cleaved. POMP is then degraded by the newly formed proteasome (Heinemeyer et al.,
2004). Two other proteins have been described to play a role in proteasome formation, 
PAC1 and PAC2 (proteasome assembling chaperone), and are thought to form 
heterodimers that associate with proteasome precursors and are degraded after 20s 
formation (Hirano et al., 2005).
1.2.4 Regulation of Proteasome activity
As 20s proteasomes are thought to exist in a latent state (due to channel closure and 
therefore inability of proteins to access the proteolytic sites within the pore) and are 
implicated in numerous cellular functions, it is essential that there are a variety of 
mechanisms in place to regulate its activity. A number of proteins and complexes have 
been identified (such as 19s, l l s ,  PA200 and PI31K) which can bind to the 20s 
proteasome and alter its proteolytic profile (Rechsteiner and Hill, 2005).
19s complexes bind to the 20s a-ring and are thought to open the 20s channel. Studies 
have shown that the 19s regulatory complex, and subsequent 26s formation, enhances 
the catalytic activity of the proteasome by approximately 2-3 fold (Hoffman and 
Rechsteiner, 1994).
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Both 1 ls a /p  complexes and llsy  rings can also bind to the 20s a-ring and alter the 
proteolytic activity of the 20s core particle. Whilst it has been shown that 1 lsa/(3 
complexes markedly stimulate all three catalytic activities to a greater extent than 19s 
regulatory complexes (by as much as 60x depending on the substrate used) (Dubiel et 
al., 1992; Ma et al., 1992), l lsy  exhibits a different pattern of activation with 
stimulation of trypsin-like activities and relative inhibition of chymotrypsin-like and 
PGPH activities (Li et al., 2001; Li and Rechsteiner, 2001).
PA200 is a 200 kDa protein (which also has 160 and 60 kDa variants) that was 
originally identified from its association with proteasomes in rabbit reticulocyte 
lysates (Hoffman et al., 1992; Ustrell et al., 2002). PA200 has been shown to stimulate 
all three catalytic activities of the proteasome, particularly chymotrypsin-like activity 
(Ustrell et al., 2002), and has been shown to bind to 20s a-subunits and subsequently 
open the 20s channel (Ortega et al., 2005).
A relatively small 31 kDa protein, PI31K, purified from bovine red blood cells (Chu- 
Ping et al., 1992) has been shown to inhibit both chymotrypsin-like and PGPH 
activity, but leave trypsin-like activity relatively unaffected. Further in vitro  
investigations have revealed that PI31K can bind to 20s core particles and compete 
with both l l s  (Zaiss et al., 1999) and 19s regulatory complexes (McCutchen-Maloney 
et al., 2000), implying that PI31K also binds via the 20s a-subunits.
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It has also been shown that under certain conditions, such as stimulation with 
interferon-y, p„ |32 and p5 subunits can be replaced by “immunoproteasome” subunits 
(LMP2, MECL-1 and LMP7, respectively), which display different proteolytic 
activities. Immunoproteasomes typically display enhanced trypsin-like and decreased 
PGPH and chymotrypsin-like activities (Dahlmann et al., 2000).
Other proteins, such as valosin-containing protein (VCP or p97), could indirectly 
affect the rate of proteasomal breakdown in a cell. VCP is an abundant 97 kDa protein 
that binds to both polyubiquitin chains and components of the 26s proteasome. It is 
thought to act as a shuttling factor and has been demonstrated to be involved in the 
targeting of polyubiquitinated substrates to the proteasome (Dai et al., 1998). Loss of 
VCP function has been shown to result in a build up of ubiquitinated proteins (Dai and 
Li, 2001). Interestingly, VCP has been shown to be present, with Dorfin (an E3 ligase 
with which it interacts), in ubiquitinated aggregates from post mortem Parkinson’s 
disease and amyotrophic lateral sclerosis (ALS) tissue and has been suggested to play 
a role in their formation (Ishigaki et al., 2004).
1.2.5 The proteasome in HD and other polyglutamine disorders
The accumulation of insoluble, ubiquitinated, mutant protein-containing aggregates in 
polyglutamine diseases strongly favours the implication that the cell is unable to fully 
degrade these novel proteins. As N ils are immunopositive for antibodies against
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ubiquitin, it seems unlikely that there is a perturbation of the enzymatic mechanisms 
involving ubiquitination. It has been postulated that proteins with expanded 
polyglutamine tracts may undergo impaired cleavage, accumulate within the central 
proteolytic chamber of the proteasome and inactivate it (Goellner and Rechsteiner,
2003).
As Nils and DNIs in HD have been shown to contain both huntingtin protein and 
ubiquitin, it has been assumed that it is the huntingtin protein within inclusions that is 
ubiquitinated. As a number of proteins are present in aggregates, it is possible that 
proteins other than mutant huntingtin are ubiquitinated. However, an in vitro study has 
shown that expression of a truncated huntingtin protein (1-540 amino acids of 
huntingtin including 44 glutamines) interacts with a ubiquitin-conjugating enzyme, 
hE2-25K, in the yeast two-hybrid system. Furthermore, huntingtin is a target for 
ubiquitination in transformed lymphoblasts derived from a patient heterozygous for 
HD (Kalchman et al., 1996).
Studies on transfected cells have yielded conflicting reports as to w hether 
polyglutamine containing proteins can (Michalik and Van Broeckhoven, 2004) or 
cannot (Holmberg et al., 2004; Venkatraman et al., 2004) be degraded by the 
proteasome. In a conditional mouse model of HD, reduced numbers of inclusions were 
detected (in a proteasome-dependent manner) when expression of the transgene was 
suppressed, indicating that in vivo, polyglutamine containing aggregates can be
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degraded after formation and that this occurs via the proteasome (Martin-Aparicio et 
al., 2001).
Equally unclear is whether expanded polyglutamine stretches actually inhibit the 
proteasome or not. Studies from transfected cells expressing truncated N-terminal 
huntingtin (Jana et al., 20Q1; Waelter et al., 2001; Rangone et al., 2005) and aggregates 
of polyglutamine containing proteins (Bence et al., 2001) have resulted in varying 
degrees of proteasomal impairment. However, in vivo studies have produced 
inconsistent results. One study measuring chymotrypsin and PGPH proteolysis in HD 
patient brains and fibroblasts, found that both activities were decreased (Seo et al.,
2004). However, this study measured total proteolysis (both proteasomal and non- 
proteasomal protease) and did not measure trypsin peptidase activity. A recent paper 
has underlined the importance of all the three main proteolytic activities of the 
proteasome being assayed to ascertain a thorough view of proteasome function 
(Kisselev and Goldberg, 2005). In another study, where all three peptidase activities 
were assayed in the HD94 conditional mouse model of HD, selective increases were 
demonstrated in trypsin and chymotrypsin like activity. This was attributed to 
increased expression of immunoproteasome subunits LMP2 and LMP7, which were 
shown to be present in very few aggregates in the HD94 cortex (Diaz-Hernandez et al.,
2003).
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1.2.6 Ubiquitin-like proteins
Subsequent to the discovery of ubiquitin, a family of small ubiquitin-related proteins 
have been identified called ubiquitin-like proteins (UBLs). These proteins are 
categorised as UBLs based upon their tertiary structure -  the presence of a ubiquitin 
superfold or (3-grasp fold -  and not upon their primary structure, although some UBLs 
do share significant sequence homology with one another (Mayer et al., 1998; 
Hochstrasser, 2000). UBLs bind to substrate proteins through a series of E l, E2 and E3 
enzymes in a similar manner to the prototype UBL, ubiquitin, although only a few E3 
enzymes have been identified for non-ubiquitin UBLs. Additionally, as lysine side 
chains represent common binding targets for many UBLs, their binding can often be 
viewed as competitive. Attachment of various UBLs have been shown to affect 
functions as diverse as degradation, transcription, DNA repair, signal transduction, 
autophagy and cell-cycle control (Kerscher et al., 2006). Indeed, the number of UBLs, 
enzymes involved and the various functions implicated would mean that this 
mechanism rivals other post-translational modifications such as phosphorylation in 
terms of significance to the cell. Whilst many UBLs have been discovered (a trend 
which looks likely to continue), there are certain UBLs, such as SUMO, NEDD8 and 
ubiquilin (contains a UBL sequence within the larger protein sequence) that either 
have relatively well characterised or are pertinent to this study and therefore only these 
shall be discussed here.
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There are 4 identified members of the SUMO (Small ubiquitin-like modifier; also 
known as sentrin) family: SUM Ol, SUM 02, SUM 03 and relatively recently, SUM 04 
(Muller et al., 2001; Guo et al., 2004). In humans, mSUM Ol, a 101 amino acid protein 
shares ~50% sequence homology with the closely related SUM 02/3 (Muller et al., 
2001) and ~18% with ubiquitin itself (Bayer et al., 1998). Unlike ubiquitin, SUMOl is 
unable to form polypeptide chains, whereas SUM 02/3 can readily form polySUMO 
chains, implying distinct functionality (Tatham et al., 2001). SUMOylation has been 
implicated in functions such as nuclear transport, signal transduction and cell-cycle 
control (M uller et al., 2001). A dditionally, SUMO has also been shown to 
competitively bind to lysine residues on NFkBo, with ubiquitin, demonstrating that 
SUMOylation regulates the degradation of proteasomal targets (Desterro et al., 1998). 
As well as the previous example, SUMO has been shown to regulate the ubiquitination 
and therefore stability of other proteins (Buschmann et al., 2000). Furthermore, it has 
been demonstrated that there are increases in levels of SUM 02/3 conjugates in 
response to cellular stressors, such as oxidation and heat (Saitoh and Hinchey, 2000).
Out of all the UBLs identified, NEDD8 (also known as RUB1) is the protein that has 
the most similar primary sequence to ubiquitin. Whilst not acting as a direct signal for 
proteasomal degradation, NEDD8’s identified functions centre on it’s ability to 
regulate ubiquitin ligating enzymes (E3). Binding of NEDD8 to sites on target E3s 
prevents binding of E3 inhibitors (Welchman et al., 2005). This can serve to regulate 
downstream ubiquitination, and therefore degradation.
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Ubiquilin is a UBL that has been shown to interact with a variety of seemingly 
unrelated proteins and is of particular interest here because of two key facets. Firstly, 
ubiquilin proteins contain domains that allow them to bind to both polyubiquitin 
chains and key subunits of the 19s proteasome regulatory complex. These binding 
attributes imply that ubiquilin may act as shuttling protein to mediate the delivery of 
polyubiquitinated proteins to the proteasome (Ko et al., 2004). Secondly, and 
somewhat perversely, ubiquilin has been shown to decrease the degradation of certain 
proteins and also their ubiquitination. This is thought to be through competitive 
binding which would essentially block ubiquitin chain elongation (Massey et al.,
2004). Like SUMO proteins, ubiquilin can compete with ubiquitin for binding and 
therefore can alter the degradation of proteins.
1.2.7 Ubiquitin-like proteins in polyglutamine expansions diseases
Out of all of the UBLs, perhaps the most ones most implicated in neurodegeneration 
are the SUMO family. SUMOl immunoreactive Nils have been described in DRPLA 
patients and cellular models (Terashima et al., 2002). Furthermore, increased levels of 
high molecular weight SUMOl-conjugates have been described in transgenic mice 
expressing mutant ataxin-1 with an expanded polyglutamine tract as well as increased 
SUMO-1 immunoreactivity in brains of HD, DRPLA, SCA1 and MJD patients (Ueda 
et al., 2002). Indeed, the polyglutamine containing protein, ataxin-1, has been shown 
to be a target of SUMOylation, although increasing the polyglutamine tract length has
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been shown to decrease SUMO-1 binding (Riley et al., 2005). Overexpression of a 
mutant form of SUMO-1 activating enzyme in a Drosophila model of SBMA enhances 
polyglutamine induced degeneration (Chan et al., 2002). Additionally, and perhaps 
more pertinent to this study, SUMOylation of mutant huntingtin exon 1 fragments in 
Drosophila model of HD exacerbated neurodegeneration, which the authors suggested 
was not simply due to competitive binding with ubiquitin for lysine residues (Steffan 
et al., 2004). This, taken together with a study that showed that SUMO-1 deletion or 
overexpression ameliorates or enhances N il frequency and cell death implies that 
SUMO-1 may act to accelerate polyglutamine pathology (Terashima et al., 2002). 
Interestingly, in PC 12 cells, inhibition of the proteasome resulted in the appearance of 
SUMO-1 immunopositive nuclear inclusions (Pountney et al., 2003).
There is little data concerning NEDD8 in the pathology of polyglutamine disorders. 
However, in one study examining SBMA, HeLa cells transfected with polyglutamine 
expanded androgen receptor produced aggregates than were immunopositive for 
antibodies raised against NEDD8 (Stenoien et al., 1999).
To date, there are few studies examining the UBL ubiquilin in polyglutamine 
expansion diseases. In one, N-terminal Huntingtin with 150 glutamine repeats was 
expressed in Neuro2A cells and the subsequent nuclear aggregates produced were 
isolated and shown to contain ubiquilin. This was also confirmed in double-labelled 
immunofluorescence studies in R6/2 mice, although it was unclear whether DNIs also 
stained immunopositive (Doi et al., 2004). Another recent study showed that
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overexpression of ubiquilin in HeLa cells and primary neurons reduced aggregation 
and cell death induced by overexpression of GFP-tagged Huntingtin (with 74 
glutamine repeats) (Wang et al., 2006).
1.3 The chaperone family of proteins
The molecular chaperone (heat shock) family of proteins are a group of proteins that 
were originally identified based on their appearance during cellular stress and the 
subsequent discovery of their role in preventing protein aggregation and misfolding by 
promoting their correct conformation. Chaperones are an abundant and highly 
conserved family of cellular proteins and are widespread throughout the eukaryotic 
cell (Hard, 1996). They can broadly be classified into four subfamilies: the Hsp70 
family, the Hsp90 family, the small heat shock proteins and the chaperonins.
The Hsp70 proteins include the constitutive Hsc70 and inducible Hsp70 homologues 
as well as the Hsp40 family of co-chaperones (which serve to regulate Hsp70 
function). The action of Hsp70 proteins is ATP-dependent, and can be regulated by the 
Hsp40 proteins (and other proteins, such as BAG-1). Hsp70 proteins have been shown 
to be involved in refolding after translation and during cellular stress (Hard, 1996). 
Interestingly, two proteins, CHIP (C-terminal of Hsp-70 interacting protein) and BAG- 
1 (Bcl-2 associated gene product 1) have been shown to act as a link between the 
chaperone system and the UPS.
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The cytoplasmic Hsp90 family of proteins, also ATP-dependent, are generally thought 
to be involved in the regulation of signal transduction networks (Pratt, 1997). Hsp90 
proteins are interesting here because they have been shown to be involved in the 
regulation (suppression) of chymotrypsin-like and PGPH activities of the proteasome 
(Lu et al., 2001).
The role of the ATP-independent small heat shock proteins (sHsp’s), which include 
Hsp27 and aB-crystallin, is not well understood, although they have an established 
role in preventing aggregation formation under cell stress. Typically, they exist as an 
active dimer and have been known to function alongside other chaperones (eg.Hsp70).
The chaperonin family (eg. Hsp60) seems to function slightly differently from the 
other chaperones in that they form a barrel-like structure as a prerequisite to activity. 
Chaperonins are, for example, involved in the folding of the cytoskeletal protein actin 
(Martin and Hard, 1997).
1.3.1 Chaperones in other polyglutamine expansion diseases
There is a breadth of data to suggest that chaperones are involved in the pathology of 
polyglutamine diseases. Several studies have detailed the co-localisation of chaperones
(particularly Hsp70 and Hsp40) with aggregates in models of polyglutamine diseases 
(Cummings et al., 1998; Stenoien et al., 1999; Warrick et al., 1999; Jana et al., 2000).
Furthermore, decreases of Hsp70 and Hsp27 have been described in transformed 
lymphoblastoid cells from SCA-7 patients (Tsai et al., 2005). It is possible that either 
sequestration in aggregates or a reduction in chaperone levels could contribute to the 
formation of aggregates and toxicity of expanded polyglutamine containing proteins. 
There is evidence to support this in an in vitro model expressing exon 1 of Huntingtin 
(with 150 glutamines), where reduced numbers of aggregates and decreased toxicity 
are exhibited when cells are co-transfected with the brain-enriched chaperone, MRJ 
(Chuang et al., 2002). Other studies have also demonstrated a cell-protective effect of 
chaperones on polyglutamine-induced pathology including a reduction in aggregation 
(Warrick et al., 1999; Cummings et al., 2001; Novoselova et al., 2005).
1.4 Aims of the project
This study aims to examine the role of the UPS in the R6/2 mouse line (Mangiarini et 
al., 1996), an established model of HD and attempts to shed light into several key 
questions regarding the neuropathology in this model: What is the ultrastructure of the 
aggregates in this model? Is it the huntingtin protein that is ubiquitinated in these 
mice? What proteasome components / chaperones are recruited to the aggregates and 
do the Nil and dNI differ with respect to what they recruit? And importantly, if
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proteasomes are sequestered into aggregates, does this result in loss of function of the 
proteasome? Do polyubiquitinated aggregates sequester other UPS-associated 
proteins? Assessing the localisation, function, activity and regulation of the UPS in 
this model could provide useful insights into the fundamental mechanisms of 
neuropathology in HD.
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CHAPTER 2
Materials and Methods
2.1 Materials
2.1.1 Standard solutions
Primary antibody buffer: 0.002% (w/v) sodium azide, 0.3% (v/v) Triton-X 100, 0.1 M 
Tris pH7.4
Phosphate buffer pH7.4: 77 mM Na2H P04, 23 mM NaH2P 0 4, pH7.4
2.1.2 Transgenic mice
All mouse husbandry and experimental procedures were carried out in accordance with 
UK Home Office regulations and the Animals (Scientific Procedures) Act, 1986. The 
mice used in this study were either 13 week-old transgenic R6/2 (described previously) 
or age-matched litter-mate controls (referred to as wild-type or WT herein). R6/2 mice 
were donated by Professor Gillian Bates (King’s College, London) and maintained by 
backcrossing R6/2 males with (C57BL/6 x CBA) FI females (Harlan Olac, Bicester, 
UK). Only female mice were used in this study.
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Mice were anaesthetised with an overdose of sodium pentobarbitone (Sagatal, 100 
mg/kg, intraperitoneally) and perfused through the left cardiac ventricle with the 
appropriate fixative / solution.
2.2 Microscopy methods
2.2.1 Preparation of tissue for immunohistochemistry or immunofluorescence
Animals were perfused with 35-50 ml of PLP (2% (w/v) paraformaldehyde / lysine / 
periodate fixative in phosphate buffer pH7.4). The brains were carefully removed, 
submersed in PLP for 4-6 hours and transferred to cryoprotectant solution (30% (w/v) 
sucrose in 0.1 M Tris pH7.4) for 48 hrs at 4  °C. Brains were mounted on a SM2000R 
sledge microtome (Leica) with Tissue-Tek Oct compound (Miles Laboratories) and 
frozen with powdered solid C 0 2. Sections were cut in the coronal plane (40 pm) and 
transferred to a dimple tray with 0.1 M Tris pH7.4.
2.2.2 Preparation of tissue for electron microscopy
Animals were perfused with 35-50 ml of EM fixative (4% (w/v) paraformaldehyde, 
0.1% (v/v) glutaraldehyde in phosphate buffer pH7.4). The brains were carefully
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removed and placed in fresh EM fixative overnight (4 °C). Brains were mounted onto 
a Series 1000 Vibratome (Agar Scientific) with cyanoacrylate (Superglue) and 
immersed in 0.1 M phosphate buffer pH7.4. Sections were cut in the coronal plane 
(200 pm) and transferred to a dimple tray with 0.1 M phosphate buffer pH7.4.
2.2.3 Immunohistochemistry
Sections were incubated, free-floating, in primary antibody diluted in primary antibody 
buffer (1:200; see below for antibodies used) for 72 hours at 4 °C, washed* and 
transferred to biotinylated secondary antibody (1:200, diluted in 0.1 M Tris pH7.4; all 
from Vector) for 90 minutes. Sections were removed, washed* and incubated with 
ABC complex (Vectastain) in 0.1 M Tris pH7.4 for 90 minutes. Sections were washed* 
and incubated with DAB developer solution (diaminobenzidine (25 mg / 100 ml), 
0.003% (v/v) H20 2, 0.1 M Tris pH7.4) until dark brown areas of DAB reaction product 
were clearly visible. Reactions were stopped by transferring sections to 0.1 M Tris 
pH7.4. Sections were mounted onto gelatinized glass slides, air-dried overnight and 
dehydrated in a series of ethanol concentrations (5 minutes each; 70%, 80%, 90%, 
95%, 100% (v/v) x 2). Slides were cleared in Histoclear (2 x 10 minutes; National 
Diagnostics), coverslipped with DPX solution and air-dried (24-48 hours). Slides were 
viewed on a DMR light microscope (Leica) and images captured using a Canon EOS 
D30 digital camera.
* - All washes (3 x 10 minutes) were performed in 0.1 M  Tris pH  7.4
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2.2.4 Antibodies for immunohistochemistry
T he fo llow ing  proteasom e an tibodies, used fo r im m unohistochem istry , w ere all 
obtained from BIOM OL, UK:
Protein
(Yeast
nomenclature)
Protein
(Mammalian
nomenclature)
Antibody Code 
#
Species 
raised in
20s a  1,2,3,5,6 & 7 iota, C3, C9, 
zeta, C2 & C8
PW 8195 M
20s “core” 20s “core” PW8155 R
20s (31 Y PW8140 M
20s (31 i LMP2 PW8345 R
20s p li LMP2 PW8840 M
20s (32 Z PW8145 M
20s 02i MECL-1 PW8350 R
20s (33 CIO PW8130 M
20s (34 C7 PW8890 R
20s p5 X PW8895 R
20s |35i LMP7 PW8845 M
20s P5i LMP7 PW8355 R
20s (36 C5 PW9000 R
20s (37 N3 PW8135 M
19s Rptl S7 PW8165 R
19s Rptl S7 PW8825 M
19s Rpt2 S4 PW8305 R
19s Rpt3 S6b PW8175 R
19s Rpt3 S6b PW8310 R
19s Rpt3 S6b PW8765 M
19s Rpt4 SlOb PW8220 R
19s Rpt4 SlOb PW8830 M
19s Rpt5 S6a PW8770 M
19s Rpt6 S8 PW8320 R
19s Rpn2 SI PW9270 M
19s Rpn6 S9 PW8370 R
19s Rpn7 SlOa PW8225 R
19s Rpn8 S12 PW8180 S
19s RpnlO S5a PW9250 M
19s Rpnl2 S14 PW8815 R
19s Rpnl2 S14 PW8835 M
1 Isa PA28a j PW8185 R
1 ls(3 PA28(3 PW8240 R
1 lsy PA28y PW8190 R
55
NB: 20s “core ” antibody recognises a5/zeta, a7!C8, plIY, p5/X, (35i/LMP7 and f$7/N3 
subunits.
The following antibodies were also used for immunohistochemistry:
BAG (Santa Cruz Biotech., SC-939), CHIP (Abeam, AB2917), E2-25k (BIOMOL, 
UG9520), Hsp27 (Santa Cruz Biotech., SC-1049), Hsp40 (Santa Cruz Biotech., SC- 
1801), HDJ-2 / DNAJ (Neomarkers, MS-225-P1ABX), Hsp70 (Santa Cruz Biotech., 
SC-1060), Hsp70 (Stressgen Biotech., SPA-810), Hsc70 (Santa Cruz Biotech., SC- 
1059), Hsc70 (Stressgen Biotech., SPA-815), Hspl05 (Santa Cruz Biotech., SC-1804), 
Huntingtin (EM48) (Chemicon, MAB5374), Huntingtin N-18 (Santa Cruz Biotech., 
SC-8767), Glutamyl lysine isopeptide bonds (Abeam, AB422), NEDD8 (Santa Cruz 
Biotech., SC-5480), PI31 (Abeam, AB3893), Polyglutamine (1C2) (Chemicon, 
MAB1574), POMP (BIOMOL, PW 9715), PA200 (Abeam, AB5620), SUMO 1 
(Abeam, AB11672), SUMO 2/3 (Abeam, AB3742), Ubiquilin (Abeam, AB3341), 
Ubiquitin (Dako, Z0458), VCP (Santa Cruz Biotech., SC-20799).
2.2.5 Double-labelled immunofluorescence
Sections were incubated, free-floating, in primary antibodies diluted in primary 
antibody buffer (see below for concentrations used) for 72 hours at 4 °C, washed* and 
then transferred to fluorophore-tagged secondary antibodies (1:100 in 0.1 M phosphate 
buffer pH7.4) for 2 hours away from light. Sections were removed, washed* and 
mounted onto gelatinized slides, coated with Vectashield mounting medium,
56
coverslipped and sealed with nail varnish (all in the dark). Slides were stored at 4  °C in 
the dark until they were viewed on an upright confocal m icroscope (Leica).
* - All washes (3 x 10 minutes) were perform ed in 0.1 M  phosphate buffer pH 7.4
2.2.6 Antibodies for immunofluorescence
The following primary antibodies were used for double-labelled im m unofluorescence:
Target protein Dilution Species raised 
in
Product
Num ber
M anufacturer
Huntingtin
(EM 48)
1:500 m ouse M A B5374 Chem icon
SUMO 1 1:200 rabbit A B 11672 Abeam
SUM O 2/3 1:200 rabbit AB3742 Abeam
Ubiquitin 1:1000 rabbit Z0458 Dako
Ubiquitin (FK2)* 1:1000 mouse SC-939 BIOM OL
As all com binations of prim ary antibodies for double-labelled im m unofluorescence 
used one prim ary antibody raised in rabbit and one in m ouse, both an ti-rabb it 
conjugated to FITC and anti-m ouse conjugated to TR ITC  (both raised in donkey; 
Jackson Im m unochem icals) were used as secondary antibodies.
* - FK2 recognises both mono and polyubiquitinated proteins, but not free  ubiquitin.
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2.2.7 Electron Microscopy
Sections were osmicated in 1% (v/v) osmium tetraoxide (diluted in 0.1 M phosphate 
buffer, pH7.4) at 4 °C for 1 hour, washed (2 x 10 mins in 0.1 M sodium acetate) and 
then en-bloc stained in 2% (v/v) uranyl acetate (diluted in 0.1 M sodium acetate) at 4 
°C for 1 hour. Sections were washed in 0.1 M sodium acetate (10 mins) and then in 
distilled water (5 mins) before dehydration through a graded ethanol series (25%, 50%, 
70%, 90%, 100% (v/v) x 4 ; 5-10 mins each). Sections were cleared of alcohol through 
washes in propylene oxide (4 x 10 mins) and placed into a 1:1 mixture of propylene 
oxide and araldite resin (10 g DDSA(dodecenyl succinic anhydite), 10 g araldite and 
0.8 g plasticizer (dibutyl pathalate)) for 45 minutes. Sections were transferred to fresh 
araldite resin on a rotator for 24 hours. Sections were then blocked-out by placing 
between two sheets of Melinex (ICI), weighted down and left overnight at 60 °C. 
Sections in polymerised resin were superglued onto resin blocks and ultrathin (~70-90 
nm) sections were cut using glass knives on a Ultracut microtome (Reichert) and 
collected on copper-mesh grids. Sections were counter-stained in lead citrate, dried 
and viewed under a JEOL 1010 transmission electron microscope.
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2.3 Protein biochemistry
2.3.1 Preparation of tissue for electrophoresis
Animals were briefly perfused with cold 0.1% (w/v) NaCl with Complete protease 
inhibitor cocktail tablets (PIC) (Roche Diagnostics GmbH, 1 tablet / 25 ml). The brains 
were quickly removed and homogenised in 3 ml boiling lysis buffer (1% (w/v) SDS, 1 
mM Na3V 0 4, 10 mM Tris pH7.4 with PIC, 1 tablet / 25 ml)) using a dounce 
homogeniser. Homogenates were microwaved for 15 seconds and centrifuged (10,000 
x g, 15 °C) for 3 minutes to pellet large insoluble material. Supernatants were 
collected, aliquoted and stored at -8 0  °C. Total protein concentrations were measured 
using a modified Lowry assay (DC protein assay, Biorad). Aliquots of two R6/2 and 
two LMC samples were used for all western blot experiments and equal loading of 
samples was confirmed through initial western blots using antibodies against y-tubulin.
2.3.2 SDS-PAGE
Samples were denatured at 95 °C for 3 mins) in 3 x sample buffer (125 mM Tris 
pH6.8, 15% (v/v) glycerol, 10% (v/v) |3-mercaptoethanol, 4% (w/v) SDS, 0.05% (w/v) 
bromophenol blue). Precast polyacrylamide gels (either 4-15% or 4-20% (Biorad) 
were loaded into Mini Protean II systems (Biorad) containing cold running buffer (25 
mM Tris, 192 mM glycine, 0.1% (w/v) SDS, pH8.8). Samples of total protein (10 or
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20 pg) were loaded per lane. Biotinylated protein ladder (0.5 or 1 pi, Cell Signalling 
Technology, Inc.) was used to act as molecular weight markers. Samples were 
electrophoresed at 45 mA, 200 V until the tracking dye reached the end of the gel.
2.3.3 Western blotting
Gels were equilibriated in transfer buffer (50 mM Tris, 40 mM glycine, 20% (v/v) 
methanol) for 1 hour. Proteins were blotted overnight (30 v, 90 mA) onto 
nitrocellulose membranes (Amersham Pharmacia Biotech.) in ice-cold transfer buffer 
using a Mini Transblot (Biorad). Membranes were washed (10 mins) in wash buffer 
(50 mM Tris pH 7.4, 80 mM NaCl, 40 mM glycine, 2 mM CaCl2, 0.2% (v/v) Igepal 
CA-630) and then incubated in blocking buffer (5% (w/v) non-fat dried skimmed milk 
power (eg.Marvel) in wash buffer) for 2 hours. After blocking, membranes were 
incubated for 1 hour with primary antibodies diluted in blocking buffer. Membranes 
were washed in wash buffer (3 x 10 minutes) and incubated with HRP-conjugated 
secondary antibodies (Calbiochem) and HRP-conjugated anti-biotin antibody 
(1:20,000) diluted in blocking buffer for one hour. Secondary antibodies were used at 
the following concentrations: anti-mouse (raised in goat), 1:20,000; anti-rabbit (raised 
in goat), 1:10,000; anti-goat (raised in rabbit), 1:5,000. Membranes were washed in 
wash buffer (3 x 10 mins), developed using ECL Plus kits (Amersham Pharmacia 
Biotech) according to manufacturers instructions and exposed onto Hyperfilm ECL 
(Amersham Pharmacia Biotech.).
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2.3.4 Antibodies for western blotting
Target protein Dilution Species raised 
in
Product
Number
M anufacturer
20s ctj 23567 1:2500 m ouse PW 8140 BIOM OL
20s (3, 1:2500 mouse PW 8145 BIOM OL
20s p2 1:2500 mouse PW 8895 BIOM OL
20s p5 1:2500 rabbit PW 8195 BIOM OL
BAG 1:250 rabbit SC-939 Santa Cruz 
Biotechnology
CH IP 1:750 rabbit AB2917 Abeam
E2-25k 1:4000 rabbit UG9520 BIOM O L
Hdj-2 1:250 mouse M S-225P0 Neom arkers
Hsc-70 1:250 goat S C -1059 Santa Cruz 
Biotechnology
Hsp-40 1:250 goat S C -1801 Santa Cruz 
Biotechnology
Hsp-70 1:250 goat S C -1060 Santa Cruz 
B iotechnology
Huntingtin
(EM 48)
1:1250 m ouse M AB5374 Chem icon
Huntingtin N- 
18
1:200 goat SC-8767 Santa Cruz 
Biotechnology
Isopeptidase 1:250 m ouse AB422 Abeam
LM P2 1:2000 rabbit PW 8205 BIOM O L
LMP7 1:2000 rabbit PW 8200 BIOM O L
MECL-1 1:2000 rabbit PW 8150 BIOM O L
NEDD8 1:250 goat SC-5480 Santa Cruz 
Biotechnology
PA 28a 1:4000 rabbit PW 8185 BIOM OL
PA28p 1:4000 rabbit PW 8240 BIOM O L
PA28y 1:4000 rabbit PW 8190 BIOM O L
PI31 1:500 goat AB3893 Abeam
Polyglutamine
G C 2)
1:4000 mouse M AB1574 Chem icon
POM P 1:1000 rabbit PW 9715 BIOM OL
PA 200 1:2000 rabbit AB5620 Abeam
SUM O 1 1:2000 rabbit A B 11672 Abeam
SUM O 2/3 1:2000 rabbit A B3742 Abeam
Ubiquilin 1:750 rabbit AB3341 Abeam
Ubiquitin 1:5000 rabbit Z0458 Dako
V CP 1:500 rabbit SC-20799 Santa Cruz 
Biotechnology
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2.3.5 Coomassie blue staining
To confirm equal lane loading, total protein was Coomassie stained on post-transfer 
gels. Gels were incubated with staining solution (35% (v/v) methanol, 15% (v/v) 
glacial acetic acid, 0.1% (w/v) Coomassie brilliant blue R-250 (Biorad)) until bands 
were visible, then rinsed (changed every 30 minutes) in destaining solution (35% (v/v) 
methanol, 15% (v/v) Glacial acetic acid) until background was clear. Gels were placed 
in drying frame (BioDesign Inc.) and air-dried.
2.3.6 Preparation of tissue for immunoprecipitation
Animals were briefly perfused with cold 0.1% (w/v) NaCl with protease inhibitor 
cocktail tablets (PIC) (1 tablet / 25 ml). The brains were quickly removed and 
homogenised in 3 ml SIP buffer (0.1 M phosphate buffer, pH7.4, PIC 1 tablet / 25 ml) 
using a Dounce homogeniser. Lysate protein concentrations were determined using a 
modified Lowry assay (DC protein assay, Biorad) and samples were diluted with SIP 
buffer to a concentration of 500 pg / ml.
2.3.7 Immunoprecipitation of ubiquitinated proteins
50 pi of magnetic Dynabeads coupled to protein G (Dynal Biotech) were washed twice 
in 0.5 ml IP buffer (0.1 M phosphate buffer, pH7.4, 0.01% (v/v) Tween-20) and
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resuspended in 50 pi IP buffer. Beads were incubated with FK2 antibody (BIOMOL) 
for 2 hours at room temperature with gentle mixing on a rotorwheel, washed and 
resuspended in 50 pi IP buffer. 1 ml of sample homogenate was added to beads and 
incubated overnight at 4 °C with rotation. Beads were washed 3 times in 1 ml 
phosphate buffer (pH7.4), resuspended in 20 pi sample buffer, electrophoresed and 
blotted with 1C2 antibody.
All mixes were performed on a slow rotorwheel. All separation of Dynabeads from 
solution was performed using a magnet (Dynal Magnetic Particle Concentrator, Dynal 
Biotech.).
2.4 Proteolysis activity assays
2.4.1 Preparation of tissue for proteolysis assays
This proteolytic activity assay was based upon the methods of Keller et al.. Animals 
were perfused with ice-cold 0.1% (w/v) NaCl. Brains were quickly removed and 
homogenised in proteolysis assay buffer (5 mM MgCl2, 5 mM ATP, 0.5 mM DTT, 10 
mM Tris pH7.4) using a Dounce homogeniser. Lysate protein concentrations were 
determined using a modified Lowry assay (DC protein assay, Biorad) and samples 
were diluted with proteolysis assay buffer to a concentration of 1 pg / pi.
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2.4.2 Proteolytic activity assay
SDS is a known activator of the 20s proteasome (Shibatani and Ward, 1995). For 
proteolysis activity assays in the presence of SDS, detergent was added to give a final 
concentration of 0.03% (w/v). 250 pi of sample and 2.5 pi of fluorogenic substrate (5 
mM in DMSO) were incubated in 96-well plates for 30 minutes at 37°C. Proteolytic 
activity, as determined by the cleavage of fluorogenic substrate, and subsequent 
fluorescence generated was measured and recorded (every 30 mins for 4 hours, 37 °C) 
using a Fluostar Optima fluorimeter connected to a PC running the Optima analysis 
package (BMG Labtech Ltd.). Parameters (eg. gain of fluorescence, excitation / 
emission filters) were optimised for samples prior to experiment. All experiments were 
repeated in triplicate and averaged.
The following fluorogenic substrates were used: Succinyl-Leu-Leu-Val-Tyr-AMC 
(BIOMOL) was used to measure chymotrypsin-like proteolysis; Boc-Leu-Arg-Arg- 
AMC (BIOMOL) was used to measure trypsin-like proteolysis; Z-Leu-Leu-Glu-AMC 
(BIOMOL) was used to measure PGPH-like proteolysis.
2.4.3 Proteasomal and protease activity assay
To differentiate between protease and proteasomal proteolysis, assays were performed 
with and without proteasomal inhibition. Epoxomicin is the most specific proteasomal
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inhibitor currently known and its only identified function is inhibition of the 
proteasome (Dr. Alexei Kisselev, Dartmouth Medical School, USA, personal 
communication). Assays were performed as above, except either 2.5 pi of 2.04 mM 
epoxomicin (BIOMOL) in DMSO or 2.5 pi DMSO alone (no inhibition) was added in 
addition to the fluorogenic substrate. This addition of inhibitor produces a final 
concentration of 20 pM epoxomicin, which is sufficient to inhibit chymotrypsin-like, 
trypsin-like and PGPH-like proteolytic activities of the 20s proteasome. Any activity 
in the presence of epoxomicin is considered to be non-proteasomal or protease 
proteolytic activity, and the difference between proteolysis in the presence and absence 
of epoxomicin (ie. epoximicin-sensitive component) is considered to be proteasomal 
activity.
2.4.4 Statistics
The unpaired student’s t test was used to statistically evaluate the data from proteolytic 
activity assays and was perform ed both using M icrosoft Excel and online 
(h ttp://w w w .phvsics.csbsju.edu/stats/t-test.htmD. Differences were described as 
statistically significant when p  values were below 0.05.
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CHAPTER 3
Results
3.1 Overview
The initial aim of this project was to understand the nature of the insoluble protein 
aggregates found in the neurons of R6/2 mice and what role the UPS plays in the 
neuropathology of this neurodegenerative model. Firstly, electron microscopy and 
western blot analysis were used to demonstrate that aggregates are generally 
amorphous structures that are likely to be formed by the process of transglutamination 
(chapter 3.2.1). Confocal and immunoprecipitation studies were used to demonstrate 
that co-localisation of huntingtin and ubiquitin immunoreactivity in aggregates was 
due to direct ubiquitination of mutant huntingtin protein (chapter 3.2.2). To determine 
whether proteins involved in degradation (20s, 19s and 11s proteasome components) 
and folding (chaperones) displayed altered localisation in the R6/2 model, detailed 
immunohistochemical studies were carried out and showed redistribution of many of 
these proteins to aggregates (chapters 3.2.3-4).
As aggregates were shown to contain ubiquitinated mutant protein and many 
components of the ubiquitin-proteasome system, experiments were carried out to 
measure proteolysis in brains of R6/2 mice. These fluorometric-based assays revealed
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increases in both chymotrypsin-like and PGPH-like and decreases in trypsin-like 
proteasomal activities (chapters 3.3.1-2). Additionally, all three activities were found 
to be decreased in non-proteasomal proteases. To explain the differential proteolytic 
profile found in R6/2 mice, the individual P-subunits responsible for the chymotrypsin- 
like, PGPH-like and trypsin-like activities of the proteasome were analysed by western 
blotting (chapter 3.3.3): The majority of p i  and P5 subunits (chymotrypsin-like, 
PGPH-like) were found to co-sediment with the aggregates, whilst the P2 subunit, 
responsible for trypsin-like proteolysis, was shown to be predominantly present in the 
immature propeptide form.
To try to explain the increases seen in chymotrypsin-like and PGPH-like activities, 
western blotting was used to analyse levels of proteins known to regulate and alter the 
activities of the proteasome (chapters 3.4.1-3). No changes were seen in levels of 11s 
or immunoproteasome subunits, whilst increases were demonstrated in 19s protein 
levels. PA200 levels appeared increased in R6/2 brains and were shown to relocate to 
inclusions. Levels of PI31K, an inhibitor of chymotrypsin-like and PGPH-like 
peptidase activities, were demonstrated to be decreased in R6/2 brains.
Finally, immunohistochemical, confocal and western blotting analyses were used to 
ascertain the localisation and levels of additional proteins involved in the ubiquitin- 
proteasome system, such as those involved in ubiquitination and proteasomal 
maturation (E2(25k) and POMP) or ubiquitin-like proteins (SUMO-1, SUMO-2/3,
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ubiquilin and VCP) (chapter 3.5.1-2). E2(25k), POMP and the ubiquitin-like proteins 
were shown to redistribute and insolubilise with aggregates.
3.2 Molecular composition of aggregates in R6/2 transgenic mice
One of the pathological hallmarks of polyglutamine diseases is the presence of 
insoluble Nils, yet relatively little is known about their structure and molecular 
composition. Therefore, a series of experiments were conducted to further understand 
the structure and composition of the aggregates found in the R6/2 model.
3.2.1 Aggregates are amorphous structures containing Ne(y glutamyl) lysine 
bonds
The two prevailing hypotheses concerning the structure of aggregates in polyglutamine 
disease state that expanded polyglutamine-containing proteins either form fibrils made 
up of hydrogen bonded P-pleated sheets or aggregate through the isopeptide cross links 
formed by the enzyme transglutaminase (Hoffner and Djian, 2002).
Transmission electron microscopy was used to examine the ultrastructure of 
aggregates in 13 week-old R6/2 mice. Cortical N ils appear as predominantly 
amorphous, granular structures (Figure 7A & C) without the typically fibrous
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ultrastructure that is clearly visible in aggregates in other neurodegenerative diseases, 
such as Lewy bodies in Parkinson’s disease. From a purely ultrastructural viewpoint, 
Nils do not seem to exhibit a defined ultrastructure characteristic of |3-pleated fibrils. 
DNIs display a very similar granular morphology to nuclear aggregates. However, 
what can be construed as a fiber can occasionally be seen in neurite aggregates, it is 
important to state that these are the exception and not the norm (Figure 7B).
The commercial availability of antibodies against Ne(y glutamyl) lysine bonds, the 
specific isopeptide links formed by transglutamination, allows for analysis of the 
mechanism of aggregation in neurodegenerative disease. Western blotting using such 
antibodies in R6/2 mice shows the presence of these isopeptide cross links in R6/2 
mice as a smear from ~70 kDa upwards to the well of the gel (Figure 7D). 
Additionally, distinct bands appear at ~140, 210 kDa, possibly representing dimers and 
trim ers of m utant huntingtin protein. These results support a role for 
transglutamination in the formation of aggregates in the brains of R6/2 mice.
Immunohistochemical analysis was employed to try and detect Ne(y glutamyl) lysine 
bonds in aggregates. This proved unsuccessful, despite repeated attempts.
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Figure 7: Inclusions in the R6/2 mouse model. Transmission electron micrographs showing 
the ultrastructure of cortical neuronal inclusions in 13 week-old R6/2 mice. Nils (A, previous 
page, arrow) can be seen to have a predominantly granular and amorphous structure, similar in 
appearance to DNIs (B). However, DNIs occasionally contain fibres (B, arrows), not seen in 
Nils, even at high magnification (C). (D) Whole-brain homogenates from 13 week-old R6/2 
mice and age-matched litter-mate controls were separated by 4-20% SDS-PAGE (10 pg total 
protein per lane) and blotted with antibodies against Ne(y glutamyl) lysine bonds. The 
antibody detected transglutaminated aggregated proteins as a smear in R6/2, but not LMC 
samples.
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3.2.2 Expanded polyglutamine proteins are ubiquitinated in R6/2 mice
Co-localisation of huntingtin and ubiquitin in Nils and DNIs was demonstrated using 
double-labelled immunofluorescence in 13 week-old R6/2 mouse cortex (Figure 8A & 
B). All huntingtin-positive inclusions were also immunopositive for antibodies against 
ubiquitin. Whilst it has been shown in transformed cell lines that constructs of 
huntingtin can be ubiquitinated (Kalchman et al., 1996), mutant huntingtin protein has 
not yet been demonstrated to be directly ubiquitinated in R6/2 transgenic mice. Indeed, 
it is possible that the ubiquitin-immunopositivity of aggregates is due to ubiquitination 
of proteins other than huntingtin. Therefore, immunoprecipitation experiments were 
used to ascertain whether mutant huntingtin protein is ubiquitinated in the R6/2 model.
Initially, to show that expanded polyglutamine containing proteins can be detected in 
R6/2 mice with 1C2 antibody, western blots were performed on R6/2 and LMC whole 
brain homogenates. The 1C2 antibody, originally raised against the polyglutamine 
stretch in TATA-binding protein, is known to have an increasing affinity for 
increasingly long polyglutamine stretches (Trottier et al., 1995). As expected, the 
presence of aggregated mutant protein appeared as a smear from approximately 70 
kDa up to the well of the gel in R6/2, but not litter mate control samples (Figure 8C). 
This is in agreement with the expected size of the transgene protein in the R6/2 model 
(Davies et al., 1997).To determine whether expanded polyglutamine containing 
proteins were ubiquitinated, magnetic Protein G-conjugated Dynal beads bound to
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Figure 8: Huntingtin is ubiquitinated in the R6/2 model. (A, B) Confocal images showing 
co-localisation of huntingtin (EM48 antibody, red) and ubiquitin (Dako antibody, green) in 
cortical inclusions of 13 week-old R6/2 mice. Overlap, and hence co-localisation, is shown 
in yellow. (C) Whole-brain homogenates from R6/2 & LMC mice were separated by 4-20% 
SDS-PAGE (10 pg total protein per lane) and blotted with anti-polyglutamine antibody (1C2). 
The antibody detected aggregated expanded polyglutamine-containing protein as a smear from 
~70 kDa upwards in R6/2, but not LMC samples. (D) Polyglutamine containing proteins were 
purified by immunoprecipitation with FK2 anti body-bound magnetic Dynal beads from 13 
week-old R6/2 and LMC whole-brain homogenates and separated by 4-20% SDS-PAGE. 
Membranes were then blotted with 1C2 antibody. A prominent smear from ~25 kDa upwards 
was detected in R6/2, but not LMC samples. The faint bands detected at ~22 and 55 kDa in 
both samples reflect the light and heavy chains of the non-covalently bound antibody that has 
dissociated from the magnetic beads. In addition to the smear detected in the R6/2 sample, the 
bands detected at ~70, 30, 18 and 15 kDa probably reflect proteolytically cleaved fragments of 
ubiquitinated polyglutamine-containing mutant protein. Scale bar 40 pm upper panels, 0.5 pm 
lower panels.
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FK2 antibody (detects mono- and poly-ubiquitinated proteins, but not free ubiquitin) 
were used to purify ubiquitinated proteins from whole-brain homogenates in 13 week- 
old R6/2 and age-matched litter mate controls. These immunoprecipitated proteins 
were then electrophoresed and blotted with 1C2 antibody. A prominent smear (from 
~25 kDa upwards) was detected in the R6/2, but not litter mate control, sample 
indicating that mutant huntingtin is indeed ubiquitinated in the R6/2 model (Figure 
8D). Additionally, the R6/2 sample lane exhibited bands at ~70, 30, 18 and 15 kDa, 
possibly reflecting proteolytically cleaved fragments of ubiquitinated huntingtin 
protein. Previous studies have demonstrated that inclusions are com prised of 
huntingtin fragments of various lengths (Lunkes et al., 2002; Iuchi et al., 2003). These 
results show that, in the R6/2 line, mutant huntingtin protein is ubiquitinated and 
additionally, is cleaved into small ubiquitinated polyglutamine-containing fragments of 
mutant huntingtin.
3.2.3 20s, 19s and 11s proteasomal subunits relocate to aggregates in R6/2 brains
It has been shown that aggregates are ubiquitinated and have stained immunopositive 
for the 20s proteasome (Jana et al., 2001), yet it is not clear whether all components of 
the 26s proteasome, particularly the 19s and 11s regulatory subunits, localise to 
aggregates and whether they distribute to both nuclear and neurite aggregates in R6/2 
mice. The advent of commercially available antibodies against various subunits of the 
proteasome, its regulatory subunits and associated proteins allows for this issue to be
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addressed. Consequently, a detailed immunohistochemical study of the localisation of 
proteasome subunits in brains of R6/2 mice was performed.
Nils stained immunopositive for 20s, 19s and 11s subunits of the proteasome in cortex 
(Figures 9 & 10) and striatum (data not shown) of 13-week old R6/2 mice. W hilst 
antibodies raised against 19s subunits additionally labelled DNIs, 20s or 1 Is antibodies 
do not do so (Figure 10). Certain antibodies against 20s subunits (|31 and p6) did not 
label neuronal inclusions. Considering the demonstrated presence of the other 20s 
subunits in nuclear aggregates, this is more likely to represent either an unsuitability of 
these antibodies for immunohistochemistry or concealment of the epitopes within the 
structure of the proteasome or aggregate. Importantly, none of the antibodies raised 
against immunoproteasome subunits (P li, |32i and p5i) were able to label either 
nuclear or neurite aggregates. This absence of y-interferon inducible subunits in 
aggregates in R6/2 mice is in contradiction to findings from a previous study 
implicating them in the pathology of HD94 mice (Diaz-Hemandez et al., 2003). These 
results demonstrate that there is differential recruitment of proteasome components to 
Nils and DNIs and that immunoproteasome subunits are not recruited to aggregates in 
R6/2 mice.
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Figure 9: Components of the ubiquitin-proteasom e system localise to aggregates in R6/2 
mice. Antibodies recognising (A) polyubiquitinated proteins, (B) 20s “core”, (C) 20s a -  
subunits, (D) 19s RPN2, (E) 19s RPN10 and (F) 11s a-subunit all stain neuronal intranuclear 
inclusions in the cortex of 13-week R6/2 mice. Both anti-ubiquitin and anti-19s antibodies 
additionally stain dystrophic neurite inclusions, whilst anti-1 Is and anti-20s antibodies do not. 
Large and small arrows represent examples off Nils and DNIs, respectively. Scale bar 20 \juyi.
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Protein Antibody
C ode#
Species 
raised in
Staining of 
Nils
Staining of 
DNIs
20s a  1,2,3,5,6 & 7 PW 8195 M -
20s “core” PW8155 R *** -
20s pi PW8140 M - -
20s pii (LMP2) PW8345 R - -
20s p ii (LMP2) PW8840 M - -
20s p2 PW8145 M ** -
20s P2i (MECLI) PW8350 R - -
20s P3 PW8130 M * -
20s P4 PW8890 R * -
20s P5 PW8895 R * -
20s p5i (LMP7) PW8845 M - 1
20s P5i (LMP7) PW8355 R - -
20s P6 PW9000 R - -
20s P7 PW8135 M ** -
19s Rptl PW8165 R *** **
19s Rptl PW8825 M *** **
19s Rpt2 PW8305 R * -
19s Rpt3 PW8175 R * -
19s Rpt3 PW8310 R * -
19s Rpt3 PW8765 M *** **
19s Rpt4 PW8220 R * -
19s Rpt4 PW8830 M - -
19s Rpt5 PW8770 M * i
19s Rpt6 PW8320 R * -
19s Rpn2 PW9270 M *** **
19s Rpn6 PW8370 R - -
19s Rpn7 PW8225 R - -
19s Rpn8 PW8180 S - -
19s RpnlO PW9250 M ** *
19s Rpnl2 PW8815 R ** -
19s Rpnl2 PW8835 M * -
11 s PA28a PW8185 R * -
1 Is PA28P PW8240 R - -
11 s PA28y PW8190 R - -
Figure 10: Table showing which proteasome subunits localise to aggregates in R6/2 mice.
Table showing which proteasome subunits are present in neuronal intranuclear inclusions 
(Nils) and dystrophic neurite inclusions (DNIs) as determined by immunohistochemical 
analysis in 13 week old R6/2 cortex. Most 11s, 19s and 20s components of the UPS are 
detected in Nils, whilst only 19s subunits are detected in DNIs. system indicates level o f 
aggregate labelling. *** = high staining frequency (equivalent to that produced by ubiquitin 
or Huntingtin antibodies); ** = moderate quantity o f aggregates immunopositive; * = 
immunostaining o f aggregates rare or infrequent ; - = antibody unable to label aggregates. See 
appendix for range o f representative images to demonstrate scoring scale
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3.2.4 Chaperones relocate to aggregates in R6/2 brains
The presence of 20s, 19s and 11s complexes of the proteasome in protein aggregates 
suggests the requirement for clearance by degradation of misfolded mutant huntingtin 
protein. However, as misfolded proteins are also targets for molecular chaperones, 
immunohistochemical and western blot studies were performed to ascertain whether 
they, too, recruit to aggregates in R6/2 mice.
Out of the chaperone antibodies tested, immunohistochemical analysis showed that 
only HDJ-2 and Hsc70 labelled N ils (Figures 11 A, B & 12). All tested chaperone 
antibodies failed to label DNIs (Figure 12). Western blot analysis confirmed the 
presence of both HDJ-2 and Hsc70 in insoluble aggregates as a smear in addition to 
soluble protein (Figure 11C & D). The smear in the case of HDJ-2 is particularly 
evident from ~80 kDa upwards, probably representing chaperone-bound fragments of 
mutant huntingtin protein. Further western blot analysis of two closely related 
chaperones, Hsp40 and Hsp70, confirmed immunohistochemical data by failing to 
show any insolublisation of the respective proteins with the aggregates (Figure 1 IE  & 
F). Levels of Hsp70 were unaltered in R6/2 brains. However, levels of Hsp40 appeared 
to be reduced in R6/2 brains compared to litter mate controls. The recruitment of 
Hsc70 to inclusions, and lack of increase in Hsp70 levels is not typical of a chaperone 
response, which has been shown to involve an increase in Hsp70. These results show 
that certain  chaperones are recru ited  to N ils , but not D N Is, in
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Figure 11: Chaperones aggregate in N ils in R6/2 mice. Neuronal intranuclear inclusions in 
the cortex of 13-week old R6/2 mice are immunopositive for antibodies against (A) HDJ-2 and 
(B) Hsc70. Neither chaperones localise to dystrophic neurite inclusions. Scale bar 20^un. (C, 
D, E and F) Whole-brain homogenates from 13 week-old R6/2 mice and age-matched litter- 
mate controls were separated by 4-20% SDS-PAGE (lOpg total protein per lane) and blotted 
with antibodies against (C) HDJ-2, (D) Hsc70, (E) Hsp40 or (F) Hsp70. In agreement with 
immunocytochemistry data, immunoblots of both (C) HDJ-2 and (D) Hsc70 demonstrate that 
both chaperones insolubilise with the aggregates in R6/2 samples, as shown by the smear from 
~80 kDa upwards. Additionally, levels of soluble HDJ-2 and Hsc70 are slightly decreased (C 
& D, arrows). Levels of (E) Hsp40 are reduced in R6/2 samples compared to LMC, whilst 
levels of (F) Hsp70 appear unaltered.
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Protein Antibody
C ode#
Species 
raised in
Staining of 
N ils
Staining of 
DNIs
Hsp27 SC-1049 Gt - -
Hsp40 SC-1801 Gt - -
HDJ-2/DNAJ MS-225-P1ABX Ms ** -
Hsp70 SC-1060 Gt - -
Hsp70 SPA-810 Ms - -
Hsc70 SC-1059 Gt ** -
Hsc70 SPA-815 Rt * -
Hspl05 SC-1804 Gt - -
Figure 12: Table showing which chaperones localise to aggregates in R6/2 mice. Table 
showing which chaperones are present in neuronal intranuclear inclusions (Nils) and 
dystrophic neurite inclusions (DNIs) as determined by immunohistochemical analysis in 13 
week old R6/2 cortex. Out of the chaperones tested, only antibodies raised against HDJ-2 and 
Hsc70 localised to Nils. No chaperones were detected in DNIs. system indicates level of 
aggregate labelling. *** = high staining frequency (equivalent to that produced by ubiquitin 
or huntingtin antibodies); ** = moderate quantity o f aggregates immunopositive; * = 
immunostaining of aggregates rare or infrequent; - = antibody unable to label aggregates. See 
appendix for range of representative images to demonstrate scoring scale
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brains of R6/2 mice and are accompanied by a decrease in levels of Hsp40.
Additionally, antibodies against BAG-1 and CHIP, proteins involved in linking the 
proteasome to chaperones were subject to immunohistochemical and western blot 
analysis. However, they were unable to detect the relevant proteins in either case.
3.3 Proteolytic activity in brains of R6/2 mice
The presence of ubiquitinated Nils and DNIs in the brains of R6/2 mice, in addition to 
the redistribution of proteasomes to aggregates implies that proteasomal inhibition is a 
feature of polyglutamine disorders. The vast majority of studies of proteasomal 
activity in polyglutamine diseases have been performed on cellular models, often 
expressing vast quantities of mutant protein, which is likely to have an impact on a 
cellular system of protein degradation. Additionally, experiments have typically relied 
on measuring only one of the peptidase activities (usually chymotrypsin-like activity) 
as an indicator of proteasome activity, whereas recent data suggests that to gain a more 
accurate assessment of proteasomal activity all three main peptidase activities 
(chymotrypsin, trypsin and PGPH) should be examined (Kisselev et al., 2006).
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3.3.1 Altered total proteolysis in R6/2 mice
Initially, as a precursor to experiments specifically measuring proteasomal activity, 
total proteolytic activity was measured in the R6/2 model, as compared to wild-type. 
This was performed by assaying the emitted fluorescence, and therefore degradation, 
of AMC-conjugated substrates of chymotrypsin, trypsin and PGPH peptidase activities 
in whole brain homogenates. Measurements of fluorescence were taken every 30 
minutes over a period of 4 hours and this data were used to give average rates of 
degradation (in arbitary units of fluorescence per hour). Assays were performed both 
in the presence and absence of SDS, a detergent thought to activate and open the 20s 
channel by removing control of access to the channel pore (Shibatani and Ward, 1995). 
All activities were expressed as a percentage of litter-mate control values (Figure 13).
In the presence of SDS, trypsin-like activity was found to be unchanged at 
145.7%(±69.8%) of control values, whilst both chymotrypsin-like and PGPH-like 
activities were increased at 436.4%(±71.1%) and 435.4%(±24.1%) of control values, 
respectively.
In the absence of SDS, reflecting a more physiological state of cellular proteolysis, 
trypsin like activities are decreased at 50.7%(±28%) of control activities, whilst both 
chymotrypsin-like and PGPH-like activities are increased at 211.5%(±74%) and 
375.4%(±55.5%) of control values, respectively. These preliminary results indicate
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Figure 13: Rate of trypsin, chymotrypsin and PGPH peptidase activities in R6/2 mice. 13
week-old R6/2 and LMC whole-brain homogenates (1 pg / pi) were incubated with AMC- 
conjugated substrates specific for trypsin, chymotrypsin or PGPH pepsidase cleavage. 
Proteolytic activity was determined by measuring the emitted fluorescence over time and 
expressed as a percentage of litter mate control values. Experiments were performed either in 
the presence or absence of SDS. In the absence of SDS, trypsin-like activities are decreased 
whilst both chymotrypsin-like and PGPH activites are increased in R6/2 samples. In the 
presence of SDS, both chymotrypsin-like and PGPH activites are both increased in R6/2 
samples, whilst trypsin-like activities appear unaltered. n=2.
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that proteolysis is altered in the R6/2 model, with trypsin-like activity decreased and 
both PGPH-like and chymotrypsin-like activity increased.
3.3.2 Altered proteasomal and non-proteasomal proteolysis in R6/2 mice
To measure whether the proteolytic changes in the R6/2 are due to alterations in 
proteasomal activity, protease activity or both, fluorogenic substrates in addition to a 
specific proteasome inhibitor can be used to break down proteolysis into two 
components. Any activity in the presence of the specific proteasome inhibitor, 
epoxomicin, is considered to be non-proteasomal or protease dependent, and the 
difference between proteolysis in the presence and absence of epoxomicin is 
considered to be proteasomal activity. Additionally, all assays were done in the 
absence of SDS to represent a more physiological profile of proteolytic activity.
Total trypsin-like activity was decreased by 67.6% (±2.1% ; pcO.OOl), whilst 
chymotrypsin-like (105.7% (±7.2% ; pcO.OOl)) and PG PH -like ac tiv itie s  
(94.4%(±42.2%)) were increased . Proteasomal trypsin-like activity was decreased by 
42.2%(±8%; p<0.05), whilst chymotrypsin-like (202.4% (±9.6%; p<0.001)) and 
PGPH-like activities (146.4%(±55.9%; p<0.05)) were increased. Non-proteasomal 
proteolysis of trypsin-like (86%(±2.4%; p<0.001)), chymotrypsin-like (89.5%(±3.1%; 
p<0.001)) and PGPH-like (39.3%(±15.1%; p<0.05) activities were all decreased 
(Figure 14). These results show that whilst there is inhibition of non-proteosomal
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Figure 14: Rate of trypsin, chymotrypsin and PGPH proteasomal and protease activities 
in brains of R6/2 and LMC mice. 13 week-old R6/2 and LMC whole-brain homogenates (1 
p, g / pi) were incubated with fluorophore-conjugated substrates specific for trypsin, 
chymotrypsin or PGPH pepsidase cleavage. Proteolytic activity was determined by measuring 
the emitted fluorescence over time. In order to determine whether changes in proteolytic 
activity were due to proteasomal or non-proteasomal proteolysis, experiments were performed 
either in the presence or absence of the specific proteasome inhibitor epoxomicin. Hence, (A) 
total proteolysis can be divided into (B) proteasomal and (C) non-proteasomal protease 
components. (A) Total chymotrypsin pepsidase activities are significantly increased, whilst 
trypsin pepsidase activity are significantly reduced in R6/2 samples compared to litter-mate 
controls. (B) Proteasonal chymotrypsin-like and PGPH-like activities are significantly 
increased, whilst trypsin-like proteolysis is significantly decreased in R6/2 samples compared 
to litter mate controls. (C) All three pepsidase activities are significantly decreased in non- 
proteasomal proteases in R6/2 samples compared to litter mate controls (*p<0.05, **p<0.001). 
n=3
g  25000
3 20000
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S. 10000
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proteases in R6/2 mice, the proteasome exhibits a diffential proteolytic profile, with 
both increases and decreases in its specific peptidase activities.
The data from these fluorometric experiments was used to show the relative 
contributions that the proteasome and non-proteasomal proteases make to total 
proteolysis measured in the R6/2 model. This displays a shift in favour of the 
proteasomal proteolysis (Figure 15). That is, that the proteasome is responsible for a 
greater percentage of total cellular proteolysis in the R6/2 model compared to litter 
mate control.
3.3.3 Alterations in proteasomal subunits in R6/2 mice
To determine whether levels of proteasome subunits, or any obvious post-translational 
modifications could account for the differential proteolytic profile of the proteasome in 
R6/2 mice, western blots were performed using antibodies against 20sa subunits and 
the 20s catalytic subunits, p„ p2 and p5.
Soluble levels of 20sa were increased in R6/2 mice, in addition to higher molecular 
weight aggregates (Figure 16A). Additionally, higher molecular weight species were 
detected at 55, 70 and ~95 kDa in the R6/2 mice, but not litter mate controls. Soluble 
levels of both (3j (Figure 16B) & p5 (Figure 16D) were markedly decreased, but as both 
P, and p5 proteins heavily stain the insoluble aggregates (top of gel), proteins levels of
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AProteasome Protease
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Trypsin 42.1 57.9
Chymotrypsin 66.9 33.1
PGPH 72 28
R6/2
Trypsin 74.9 25.1
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Figure 15: Relative contributions of the proteasome and non-proteasomal proteases to 
total proteolysis in brains of R6/2 and litter mate controls. (A) Table showing the relative 
percentage of trypsin, chymotrypsin and PGPH proteasomal and non-proteasomal proteolysis 
in R6/2 and LMC brains. In litter-mate controls, proteasomal proteolysis is responsible for 
~40% of trypsin-like proteolysis and ~70% of chymotrypsin-like and PGPH proteolysis. 
However, in the R6/2, ~75% of trypsin-like proteolysis and nearly all of chymotrypsin-like 
and PGPH proteolysis is proteasomal. This demonstrates that in R6/2 samples, a higher 
percentage of the total proteolysis is due to the proteasome. (B) Visual representation of data 
from (A)
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Figure 16: Altered expression / localisation of proteasome subunits in R6/2 mice. Whole- 
brain homogenates from 13 week-old R6/2 mice and age-matched litter-mate controls were 
separated by 4-20% SDS-PAGE (20 pg total protein per lane) and blotted with antibodies 
against (A) 20s a-subunits (B) 20s (Vsubunits (C) 20s (32-subunits and (D) 20s (35-subunits. 
Immunoblots demonstrate increased levels of soluble 20s a-subunits (A, arrow) in addition to 
aggregated protein (A, top of gel) and prominent bands at 55, 70 & 90 kDa in R6/2 mice 
compared to litter-mate controls. Soluble 20s |3, (B, arrow) & p 5-subunits (D, arrow) are 
almost absent in R6/2 mice, but are abundant in aggregated protein (B, D, top of gels). |32- 
subunits present in propeptide and mature cleaved states can be seen in LMC mice, whilst only 
propetide is seen in R6/2 mice (C, arrow). Higher molecular weight bands detected in R6/2 
samples (A, C and D) are probably aggregated forms of the respective subunits.
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particularly p5 can be considered to be increased, but insolubilised with the aggregate 
(Figure 16B & D), In WT brains, p2 propeptide, and mature cleaved protein can be 
detected, whilst in the R6/2, only propetide can be detected (Figure 16C). p2 subunits 
(whether in propeptide or cleaved product form) were present in the aggregate, but not 
as heavily as and p5. These results show that there is increased expression of the 20s 
proteasome, some of which has become insolubilised with the aggregate. Furthermore, 
the P2 subunit, which is responsible for trypsin-like peptidase activity, is present only 
as the immature propeptide in soluble form in R6/2 mice compared to controls.
3.4 Proteasomal regulation in R6/2 transgenic mice
The activity of the 20s proteasome is known to be modulated in a number of ways. 
Firstly, through the presence and binding of additional proteasome components such as 
19s and 11s complexes, which can bind and open the 20s pore channel and act as 
molecular chaperones by “feeding” proteins directly into the catalytic core. Secondly, 
via the y-interferon inducible immunoproteasome subunits (p ii , p2i and P5i) that 
directly replace the catalytically active P-subunits, p i ,  P2 and P5. Or thirdly, via 
accessory proteins, such as PI31k and PA200, which have recently been shown to alter 
the proteolytic profile of the proteasome.
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3.4.1 Levels of 11s and 19s proteasomal regulatory proteins in R6/2 mice
To ascertain whether proteolytic alterations shown in R6/2 mice could be attributable 
to altered regulation, western blot analysis was undertaken to determine any potential 
changes in levels of 11s and 19s components. Immunoblots showed that there was no 
difference in the levels of l i s a ,  l i s p  or llsy  between R6/2 mice and litter-mate 
controls (Figure 17A, B & C). Based on previous data showing a strong 
immunopositivity of aggregates using anti-Rpn2 antibodies, this antibody was used to 
gauge levels of 19s regulatory complexes. An increase was detected in levels of the 
19s subunit Rpn2 in R6/2 mice compared to litter-mate controls (Figure 17D). 
Previous immunohistochemical studies (chapter 3.2.3) demonstrated that 19s 
antibodies were particularly strong markers of both Nils and DNIs, yet western blot 
analysis did not detect 19s Rpn2 subunits insolubilising with aggregates as a “smear” 
(top of gel, data not shown). Likewise, none of the immunoblots of 11s subunits 
detected aggregate smears (top of gel, data not shown), including the l i s a  subunit, 
shown by immunohistochemical studies (chapter 3.2.3) to recruit to Nils. It could be 
argued, therefore, that both 11s and 19s proteins are not insolubilised with aggregates 
and represent transient components of inclusions, being sequestered purely by their 
high affinity for 20s proteasomes.
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Figure 17: Levels of 11s and 19s regulatory subunits in R6/2 mice. W hole-brain 
homogenates from 13 week-old R6/2 mice and age-matched litter-mate controls were 
separated by 4-20% SDS-PAGE (10 pg total protein per lane) and blotted with antibodies 
against (A) l i s a  (B) lls|3  (C) llsy  and (D) 19s slO (check other name) subunits. No 
differences were found in levels of 1 Is a ,  p or y subunits between R6/2 and LMC samples. An 
increase in levels of 19s Rpn2 subunits was found in R6/2 when compared to LMC samples.
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3.4.2 No change in immunoproteasome subunits
Immunoproteasomes are known to have different activity profiles to constitutive 20s 
proteasomes via substitution of the P-subunits known to possess catalytic activity. To 
see whether the differential proteolytic profile displayed in R6/2 brains was 
attributable to altered 20s proteasome composition, levels of immunoproteasome 
subunits were measured (Figure 18A, B & C). Western blot analysis revealed that no 
differences in protein levels of LMP2 (|31i) or LMP7 (|35i), and of MECL1 (|32i), 
which was barely detectable. Furthermore, none of these proteins were detected in 
R6/2 samples as aggregate smears. These results confirm previous data from 
immunohistochemical studies (chapter 3.2.3) demonstrating that immunoproteasome 
subunits are not recruited (or aggregate) with inclusions in R6/2 mice, nor is there any 
alterations to immunoproteasome subunit protein levels. This finding is contrary to a 
previous study describing upregulation of LMP2 and LMP7 subunits in HD94 mice 
(Diaz-Hernandez et al., 2003). Therefore, it is unlikely that immunoproteasomes are 
implicated in any alterations to the ubiquitin-proteasome system in R6/2 mice.
3.4.3 Levels and localisation of PA200 and PI31k
To see if there was any difference in the levels of accessory proteins that could explain 
the differential proteolytic profile demonstrated in R6/2 mice, western blot analysis of 
PA200 and PI31k proteins was undertaken.
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Figure 18: Levels of immunoproteasome subunits in R6/2 mice. Whole-brain homogenates 
from 13 week-old R6/2 mice and age-matched litter-mate controls were separated by 4-20% 
SDS-PAGE (10 pg total protein per lane) and blotted with antibodies against (A) LMP2 (B) 
MECL-1 and (C) LMP7 subunits. No differences were found in levels of immunoproteasome 
subunits (A) LMP2 and (C) LMP7 between R6/2 and LMC samples. (B) MECL-1 was barely 
detectable in both R6/2 and LMC samples.
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Western blots showed the presence of two bands (160 and 200 kDa) corresponding to 
the two described mammalian forms of PA200 in litter-mate controls. In the R6/2 
samples, these soluble forms of PA200 were not detectable, yet a high molecular 
weight smear was detected (Figure 19A), implying that PA200 has insolublised with 
the aggregate. Immunoblots using antibodies against PI31k detected the 31 kDa 
protein in the litter-mate control samples and revealed a significant decrease in levels 
in R6/2 samples (Figure 19B).
As PA200 was detected as a smear in immunoblots, implying insolubilisation with 
aggregates, immunohistochemical studies were perform ed on R6/2 brains to 
conclusively determine its presence in neuronal inclusions. PA200 was weakly 
detected in nuclear, but not neurite, inclusions (Figure 19C). Additionally, to further 
determine whether PI31k is present in inclusions immunohistochemistry was also 
performed using antibodies against PI31k. PI31k antibodies were unable to positively 
stain aggregates in the R6/2 mouse
These results demonstrate that PA200 is sequestered into Nils. Furthermore, protein 
levels of the chymotrypsin-like and PGPH-like proteasome inhibitor, PI31k, are 
greatly reduced in the R6/2 model.
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Figure 19: Altered expression / localisation of proteasome regulatory components PA200
and PI31k in R6/2 mice. (A, B) Whole-brain homogenates from 13 week-old R6/2 mice and 
age-matched litter-mate controls were separated by 4-20% SDS-PAGE (20 pg total protein per 
lane) and blotted with antibodies against (A) PA200 and (B) PI31k. (A) Immunoblots 
demonstrate decreased levels of soluble PA200 (~160 and 200 kDa) in addition to aggregated 
protein (top of gel) in R6/2 samples compared to litter-mate controls. (B) Soluble PI31k is 
markedly decreased in R6/2 samples. (C) Immunohistochemistry showing the presence of 
PA200 in neuronal intranuclear inclusions in the cortex of 13 week-old R6/2 mice. Scale bar 
20 fjun.
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3.5 Additional components of the UPS in the R6/2 transgenic model
20s proteasomes and regulatory components have been shown to redistribute to and 
insolublise with the Nils in brains of R6/2 mice. This leads to the possibility that other 
proteins involved or related to the ubiquitin proteasome system might be altered in the 
R6/2 model, in terms of protein level and recruitment to aggregates.
3.5.1 Additional components of the UPS machinery associate with Nils
To see whether there were any changes in levels or localisation of components that are 
involved with huntingtin ubiquitination or 20s assembly / maturation, western blots 
were performed using antibodies raised against the E2 enzyme shown to interact with 
huntingtin, E2(25k), and POMP.
Soluble levels of both E2(25k) and POMP (detected at 16 kDa) were reduced in the 
R6/2 compared to litter-mate control (Figure 20A & D). A longer exposure of the 
immunoblot revealed that POMP insolublised with the aggregates and appeared on 
immunoblots as a smear (Figur 20B). Additionally, E2(25k) produced a high 
molecular weight smear on the blot indicating that it had also insolubilised with the 
aggregates (Figure 20D).
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Figure 20: Altered expression / localisation of proteasom e m aturation  protein (POM P) 
and E2 ubiquitinating enzyme in R6/2 mice. (A, B, D) Whole-brain homogenates from 13 
week-old R6/2 mice and age-matched litter-mate controls were separated by 4-20% SDS- 
PAGE (20 pg total protein per lane) and blotted with antibodies against (A, B) POMP and (D) 
E25k. (A) Immunoblots demonstrate absence of soluble POMP (~16 kDa) in R6/2 samples 
compared to litter-mate controls. (B) Overexposure of nitrocellulose membranes show 
aggregated POMP appearing as a smear in western blots. (D) Soluble E25k is markedly 
decreased in addition to aggregated protein (top of gel) in R6/2 samples compared to litter- 
mate controls. (C) Immunohistochemistry showing the presence of POMP in neuronal 
intranuclear inclusions, but not dystrophic neurite inclusions in the cortex of 13 week-old R6/2 
mice. Scale bar 20ym.
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As both E2(25k) and POMP were detected as smears in immunoblots, implying 
insolubilisation with aggregates, immunohistochemical studies were performed on 
R6/2 brains to conclusively determine their presence in neuronal inclusions. POMP 
antibodies detected occasional neuronal intranuclear inclusion, but not DNIs, in 13- 
week R6/2 cortex (Figure 20C). However, E2(25k) antibodies failed to label 
aggregates immunohistochemically, although this could well be that antibodies 
suitable for western blotting are not always suitable for immunohistochemistry (and 
vice versa).
Taken together, these results demonstrate that proteins required for ubiquitination and 
UPS assembly become insolubilised and redistribute to inclusions in R6/2 mice.
3.5.2 Ubiquitin-like proteins redistribute to Nils
Among their currently identified function, both ubiquilin and VCP are known to target 
multi-ubiquitinated proteins to the proteasome. Additionally, SUMO-1, SUMO-2/3 
and NEDD8 are all bound to target proteins through a series of E l, E2 and E3 
enzymes, similar to that of ubiquitin. To see whether there were any changes in levels 
or localisation of ubiquitin-like proteins, western blots were performed using 
antibodies raised against SUMO-1, SUMO-2/3, ubiquilin, NEDD8 and VCP.
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Antibodies against NEDD8 were used for both immunocytochemistry and western blot 
analysis of R6/2 tissue. However, NEDD8 was unable to be detected in both 
immunoblots and immunohistochemistry.
Western blot analysis showed a loss of soluble SUMO-1 (14 kDa), SUMO-2/3 (14 
kDa), ubiquilin (66 kDa) and VCP (97 kDa) (Figure 21A, B, C & D), and a 
insolublisation of the respective proteins with the aggregate, as detected by smears on 
the tops of the gels. Additionally, high molecular weight conjugates of SUMO-1, at 
about 80 kDa, and SUMO-2/3, at about 110 kDa) were absent in the R6/2 samples.
As western blots of SUMO-1, SUMO-2/3, ubiquilin and VCP all appeared as smears 
or were retained in the wells, immunocytochemistry was used to conclusively 
determine their presence in aggregates (Figure 22A, B, C). All tested ubiquitin-like 
proteins (except VCP) recruited to Nils, but failed to label DNIs. Both SUMO-1 and 
SUMO-2/3 labelled a large frequency of nuclear aggregates, comparable with the 
immunopositivity of antibodies against huntingtin or ubiquitin, whilst ubiquilin 
antibodies labelled nuclear aggregates, albeit infrequently. Valoisin containing protein 
antibodies, however, failed to label aggregates. It is possible that this is due to a lack of 
suitability of the antibody for immunocytochemistry.
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Figure 21: Altered expression / localisation of ubiquitin-like proteins (UBLs) in R6/2 
mice. Whole-brain homogenates from 13 week-old R6/2 mice and age-matched litter-mate 
controls were separated by 4-20% SDS-PAGE (10 pg total protein per lane) and blotted with 
antibodies against (A) SUMO-1 (B) SUMO-2/3 (C) Ubiquilin and (D) VCP. Immunoblots 
demonstrate a loss of soluble SUMO-1 (A, ~14 kDa), SUMO-2/3, (B, ~14 kDa), ubiquilin (C, 
~66 kDa) and a decrease of soluble VCP (D, ~97 kDa) in R6/2 compared to LMC samples. 
SUMO-1, SUMO-2/3, Ubiquilin and VCP are all present in the insoluble aggregate (A, B, C, 
D, top of gel).Additionally, proteins that are conjugated with SUMO-1 (A, ~80, 45 and 40 
kDa) and SUMO-2/3 (B, ~110, 70 and 60 kDa) in LMC samples are absent in the R6/2 
samples.
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Figure 22: Redistribution of ubiquitin-like proteins in R6/2 mice. (A, B, C and D)
Antibodies against (A) SU M O -1, (B) SU M O -2/3 and (C) ubiquilin all label neuronal 
intranuclear inclusions in the cortex o f 13 w eek-old R6/2 mice. None of the antibodies 
detected dystrophic neurite inclusions. (D, E) Confocal images showing co-localisation 
o f both SUMO-1 (D, green) and SU M O -2/3 (E, green) with ubiquitin (FK2 antibody, 
red) in cortical inclusions o f 13 w eek-o ld  R6/2 m ice. O verlap , and hence co­
localisation, is shown in yellow . Note that as SUM O-1 and SU M O -2/3 only label 
nuclear inclusions and not dystrophic neurite inclusions, the overlapped im ages show 
some ubiquitin-positive inclusions that do not stain for SUMO-1 or SUM O-2/3 (shown 
by arrows in D and E). Scale bar 20 \xm.
In addition, as SUMO-1 and SUMO-2/3 normally localise in nuclear foci, double­
labelled immunofluorescence (using ubiquitin and either SUMO-1 or SUMO-2/3 
antibodies) was used to confirm that SUMO immunopositivity was labelling of nuclear 
aggregates (Figure 22D & E). Both SUMO-1 and SUMO-2/3 labelled a high number 
of ubiquitin positive nuclear aggregates. Additionally, immunofluorescence confirmed 
immunohistochemical studies that neither SUMO-1 or SUMO-2/3 antibodies label 
DNIs. These results demonstrate that, in addition to proteasomal components, UBLs 
relocate to and insolubilise with aggregates and, in the case of SUMO-1 and SUMO- 
2/3, higher molecular weight conjugates are absent in the R6/2 model.
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CHAPTER 4
Discussion
4.1 Molecular composition o f polyglutamine containing aggregates
Perhaps one of the most controversial topics within the polyglutamine expansion 
disease field is the role that protein aggregation plays in neurological dysfunction. 
Whilst it has been suggested that protein aggregates are benign neuropathological 
features, which are simply a by-product of disease, more commonly the controversy is 
whether aggregates are harmful to the affected neuron or whether they serve a 
neuroprotective role by sequestering potentially harmful soluble toxic species. One 
fact remains clear, however, and that is that protein aggregation is a feature common to 
all polyglutamine expansion diseases, and indeed many other neurodegenerative 
diseases, including Alzheimer’s and Parkinson’s diseases. Unlike the plaques and 
tangles found in Alzheimer’s patients brains and the Lewy bodies found in Parkinson’s 
disease brains, relatively little is known about the structure and composition of protein 
aggregates in polyglutamine diseases. As a deeper understanding into the structure and 
formation of these entities could provide important clues into the pathogenesis of these 
diseases, the first approach of this study was to try and ascertain more information 
regarding the structure and molecular composition of aggregates in the R6/2 model.
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4.1.1 Clues about the ultrastructure o f  protein aggregates in R6/2 mice
The two prevailing hypotheses regarding the nature of polyglutamine aggregation 
postulate that expanded polyglutam ine containing proteins either forms fibrils 
composed of P-pleated sheets or aggregates via transglutaminase crosslinking. 
Electron microscopy is an established tool to identify filamentous structures in 
neurodegenerative diseases. A good example of this is the Lewy body, found in 
Parkinson’s disease, which has been shown to be comprised of filaments of a -  
synuclein. These a-synuclein filaments are clearly visible at the electron microscopic 
level (Forno et al., 1976; Spillantini et al., 1998). Thus, using standard transmission 
electron microscopy, the ultrastructure of cortical neuronal aggregates was examined 
in R6/2 mice. Nils appeared to display a predominantly amorphous, granular structure. 
Indeed, DNIs were also found to be predominantly granular, amorphous structures, 
and, although they occasionally contained what could be construed as a filament-like 
structure, it is important to state that these were very rare and were the exception rather 
than the norm. This implies that whilst filamentous elements were very occasionally 
visible in DNIs, the underlying structure of aggregates in the R6/2 model does not 
appear to be filamentous in nature.
There are a variety of proteins that have been shown to insolubilise and / or relocalise 
with aggregates in R6/2 mice (see 4.1.2) and this heterogenous protein content could 
explain the predominantly disordered and amorphous structure seen. This, as 
mentioned, is unlike Lewy bodies in Parkinson’s disease patients, which can be clearly
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seen to be primarily composed of filaments of a-synuclein. This could represent an 
important distinction. Often, neurodegenerative disorders are clumped together based 
upon the common presence of insoluble protein aggregates, yet their differing 
localisation, composition and solubility would have different effects on the 
functionality of the cell. Furthermore, the fact that in R6/2 mice, neurite aggregates 
occasionally contain filament-like structures unlike nuclear aggregates implies that 
there might be differences in the composition of these aggregates. This could be due to 
differences between the nuclear and cytoplasmic compartments such as presence of 
certain chaperones, proteasome subtypes and other proteases which could affect the 
mechanism and kinetics of aggregation. For example, it is thought that calpains and 
cathepsins (cytoplasm ic and lysosomal proteases, respectively) cleave mutant 
huntingtin prior to inclusion formation, and that this cleaved N-terminal product has a 
high propensity to aggregate (Kegel et al., 2000; Kim et al., 2001). As cleavage via 
these proteases is thought to occur in the cytoplasmic and lysosomal compartments, 
different species of mutant protein would be expected to present in nuclear versus 
cytoplasmic aggregates, which has been demonstrated in one study (Lunkes et al., 
2002). This study has indeed highlighted differential recruitment of proteins to nuclear 
and neurite aggregates (discussed in 4.1.2).
A study which initially showed huntingtin filaments to be present in both a conditional 
mouse model of HD and HD patients, using both electron and atomic-force 
microscopy, is of particular relevance here (Diaz-Hernandez et al., 2004). A follow up 
study using these same mice showed that after shutting down transgene expression, the
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majority of huntingtin-containing inclusions were cleared, whilst a small fraction of 
Thioflavin-S-positive inclusions remained (Diaz-Hernandez et al., 2005). This implies 
that, even in a study showing huntingtin filaments present in inclusions, filaments do 
not form the main structure of polyglutamine inclusions, in keeping with the results 
presented here.
As electron microscopy implied that aggregates in R6/2 mice did not appear to be 
primarily composed of filam ents, transglutam ination represents an attractive 
alternative. In order to test whether aggregates in the R6/2 model are formed by the 
process of transglutamination, western blot and immunohistochemical experiments 
were performed using antibodies raised against Ne(y glutamyl) lysine bonds, the 
isopeptide bonds formed by transglutamination. The high molecular weight “smear” 
seen in these western blots is typical of aggregated proteins and these results imply 
that aggregated proteins in this model contain these specific bonds. Mutant N-terminal 
huntingtin expressed in the R6/2 model is approximately 70 kDa (Davies et al., 1997) 
and the additional bands seen at ~140 kDa and ~210 kDa are likely to represent 
transglutaminated dimers and trimers of N-terminal huntingtin. Indeed, it has been 
shown that inclusions in HD patients contain a broad range of N-terminal fragments 
(Hoffner et al., 2005). This result implies that N-terminal huntingtin is a target for 
transglutamination and that aggregates are formed via Ns(y glutamyl) lysine bonds, 
despite immunohistochemistry failing to reveal the presence of these Ne(y glutamyl) 
lysine bonds in either DNIs or Nils. It should be noted here that whilst this antibody 
has been used successfully in immunohistochemical studies examining a-synuclein
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cross-linking in Parkinsons disease (Andringa et al., 2004), a recent paper cautioned 
that this antibody is not consistent at recognising these bonds (Johnson et al., 2004). It 
is possible that the an tigen  is obscured  in R6/2 aggregates using 
immunohistochemistry and is only revealed upon denaturation for western blotting.
Based on the observations that N ils and DNIs are immunopositive for both huntingtin 
and ubiquitin -  confirmed in this study through confocal microscopy - it is 
understandably assumed that it is the mutant huntingtin in the R6/2 model that is 
ubiquitinated. Indeed, it has been shown that in transformed lymphoblasts derived 
from a patient heterozygote for HD that huntingtin immunoprecipitates with ubiquitin 
(Kalchman et al., 1996). However, as the possibility remains that it is other proteins 
within aggregates that are ubiquitinated, and in order to determine the situation in the 
R6/2 model, immunoprecipitation and western blotting techniques were used to answer 
this. The 1C2 antibody recognises expanded polyglutamine stretches (Trottier et al., 
1995) and was shown here to recognise mutant huntingtin in R6/2 mice as a smear 
from ~70 kDa upwards, as expected and in agreement with published data (Davies et 
al., 1997). When 1C2 antibody was used to blot against proteins immunoprecipitated 
using anti-ubiquitin antibodies from R6/2 whole-brain lysates, a prominent smear was 
detected from ~25 kDa upwards, implying that aggregated mutant huntingtin is 
ubiquitinated in the R6/2 model. Additionally, bands are detectable at ~70, 30, 18 and 
15 kDa, with the 70 kDa band most likely to represent soluble, ubiquitinated mutant 
N-terminal huntingtin and the other bands representing proteolytically cleaved 
ubiquitinated fragments. It is possible that their absence from 1C2 western blots could
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be due to their low levels that becom e concentrated upon ubiquitin-conjugate 
immunoprecipitation. It should be mentioned here that whilst this study shows that 
huntingtin protein is ubiquitinated in the R6/2 model, it does not demonstrate that 
ubiquitinated huntingtin is exclusively a proteasomal substrate. As mentioned 
previously, there are several types of poly ubiquitin chains, (Lys-11, Lys-48, Lys-63 
etc), and only Lys-48 is known to signal proteasomal degradation. However, a recent 
paper examined the ratios of polyubiquitin chains to uncojugated ubiquitin in several 
HD models, including the R6/2, and found that Lys-48 polyubiquitin chains, as well as 
Lys-11 and Lys-63 chains, progressively accumulated with the disease (Bennett et al., 
2007). The authors concluded that the UPS was impaired in HD, and combined with 
the immunoprecipitation data presented here, it seems likely that, the proteasome is a 
target, amongst other destinations, for ubiquinated huntingtin protein in the R6/2 
model.
These results demonstrate that the m utant huntingtin found in aggregates is 
ubiquitinated in R6/2 mice and at least a proportion of this is likely to be a substrate 
for proteasomal degradation. Through ultrastructural analysis, R6/2 aggregates appear 
to be generally amorphous and granular in nature implying that they are not primarily 
composed of filaments. This study also shows that N b(y glutamyl) lysine bonds are 
increased in brains of R6/2 mice, are present in aggregated proteins, and specific bands 
detected via western blot are likely to correspond to dimers and trimers of N-terminal 
mutant huntingtin. Taken together, these results suggest that nuclear and cytoplasmic 
aggregates are likely to be formed via the process of transglutamination in R6/2 mice.
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4.1.2 Protein recruitment to nuclear and neurite aggregates
Whilst some immunohistochemical and immunofluorescence studies have reported 
staining of huntingtin-positive aggregates with antibodies against proteasome subunits, 
it is unclear whether all complexes of the proteasome relocalise. Often, no distinction 
is made between nuclear and cytoplasmic inclusions and consequently, whether the 
proteins recruited to these com partm entalised aggregates differ. Indeed, this is 
compounded by the fact that often many cellular models of polyglutamine expansion 
diseases are characterised by the presence of cytoplasmic aggregates and do not 
produce nuclear aggregates. Therefore, caution should be taken in compiling data 
regarding the protein composition of aggregates from various models of polyglutamine 
disease. This study provides the first thorough immunohistochemical analysis of 
proteasomal subunits / complexes recruited to neuronal nuclear and cytoplasmic 
inclusions in the most studied model of HD, the R6/2.
There appears to be clear differences in the recruitment of proteasomal complexes to 
nuclear and cytoplasmic inclusions in the R6/2 model. Immunohistochemical analysis 
presented here showed that nuclear aggregates contained 20s and 19s complexes and 
also weakly stained immuno-positive for l i s a ,  but not l i s p  or l lsy , in a small 
proportion of nuclear aggregates. Whilst 1 lsy has been suggested to play a role in the 
pathology of HD (Goellner et al., 2003), as it is only small subset of Nils that label
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immunopositive for these proteins, it is likely that any potential role played by llsy  is 
not particularly significant. Indeed, l ls y  regulatory complexes may even localise to 
Nils purely through affinity for the concentrated pools of 20s proteasomes present. As 
llsy  are known to alter peptidase activities of the proteasome, it is likely that in this 
small subset of 1 lsy-positive Nils, proteasomes exhibit a slightly different proteolytic 
pattern to 1 lsy-negative N ils due to the presence of different proteasomal subtypes. 
Unexpectedly, this study showed that cytoplasmic aggregates only stained immuno­
positive for 19s subunits and failed to be stained by antibodies against 20s or 11s 
subunits. Although the results presented here show that antibodies recognising 
proteasome subunits generally seem to stain DNIs slightly more weakly than Nils, this 
is unlikely to account for the lack of 20s proteasome immunodetection in DNIs as both 
the 20sa and 20s “core” antibodies stain N ils intensely and fail to stain any DNIs. 
Additionally, as electron microscopic analysis of aggregates in R6/2 mice showed that 
Nils and DNIs both appeared very similar ultrastructurally, it is unlikely that 20s 
antigens are differentially obscured between these types of inclusions.
The finding that nuclear and cytoplasmic aggregates differ in terms of proteasome 
complexes is interesting for several reasons. Firstly, whilst 20s proteasomes have been 
described in the nucleus, they are predominantly thought of as cytoplasmic complexes, 
(Knuehl et al., 1996) and, as such, would be expected to be able to localise to and 
attempt to degrade cytoplasm ic aggregates. Secondly, as DNIs are strongly 
immunopositive for 19s complexes, one would expect the 20s proteasome to be there 
additionally, even if purely by affinity for protein-protein interactions with 19s
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complexes. Thirdly, and perhaps m ost pertinent to this study, this would reflect 
differences in the ability of nuclear and cytoplasmic aggregates to be degraded by the 
proteasome. The 20s complex, containing the catalytic sites is the central element of 
the proteasome, and without it the 19s and 11s subunits are largely redundant, in terms 
of protein degradation. Therefore, it follows that if cytoplasmic aggregates contain 19s 
subunits, but no 20s proteasomes, then proteasomal proteolysis is comparatively 
inactive in DNIs compared to Nils. This is not to say that proteolysis does not occur in 
the cytoplasmic aggregates; 20s proteasomes might well be present, but to a far lesser 
degree than in Nils; additionally, non-proteasomal proteases, such as calpains present 
in the cytoplasm could play a role in proteolysis-dependent formation of DNIs. One of 
the implications of differences in proteasomes present in cytoplasmic and nuclear 
aggregates is that one would expect that they should contain different length fragments 
as a result of differential proteolysis in the two compartments. Interestingly, one of the 
few papers highlighting differences between cytoplasmic and nuclear aggregates, 
demonstrated that like nuclear aggregates, cytoplasmic aggregates are made up of N- 
terminal fragments, although slightly larger in size (Lunkes et al., 2002), implying 
differences in the cleavage patterns between the two compartments. This could play a 
role in why cytoplasmic aggregates occasionally contain fibers, whilst N ils do not 
appear to.
The question remains as to why DNIs are strongly immunopositive for 19s complexes 
when there are no 20s complexes there. It is known that certain 19s subunit bind 
polyubiquitin chains and could, therefore, be recruited to aggregates containing
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ubiquitinated N-terminal mutant huntingtin. It seems strange, however, given the 19s’ 
affinity for 20s complexes that 20s complexes do not localise to DNIs.
As this study showed that N ils in R6/2 mice contained a heterogenous mix of 
ubiquitinated huntingtin, 20s and 19s proteasomes (and in some cases llsy ) , the 
possibility remained that N ils are additionally sites of proteasome formation and 
ubiquitination. To test this hypothesis, western blotting and immunohistochemical 
analysis was performed using antibodies against proteins involved in these processes. 
Proteasome maturation protein (POMP) is the mammalian homologue of UMP1, a 
yeast protein, that is thought to act as a chaperone in the complex biogenesis of 20s 
proteasomes (Witt et al., 2000). In the present study, POMP was shown to localise to a 
proportion of Nils, but not to DNIs, implying that proteasomal biogenesis takes place 
within the NIL Whether this represents a high level of 20s biogenesis in N ils or is 
indicative of incomplete maturation remains unclear. However, once again, this 
highlights another difference between N ils and DNIs, although, in this case, the 
absence of POMP was not wholly unexpected from DNIs based on this study’s 
previous observations that they are not immuno-positive for 20s complexes. Western 
blot analysis presented here revealed that soluble POMP is depleted in R6/2 mice, 
although overexposure of the blot revealed the presence of aggregated and 
insolubilised POMP appearing as a smear. It would seem understandable that, 
considering that 20s a  and p subunits form high molecular weight species, insolublise 
and aggregate, too, in the R6/2 model (discussed in 4.2.2), that POMP, which would 
bind to them would also insolubilise.
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The ubiquitination of huntingtin is still relatively poorly understood. Currently, 
huntingtin has been shown, through yeast two-hybrid screening, to interact directly 
with two enzymes involved in ubiquitination, the ubiquitin conjugating enzyme, 
E2(25k)(Kalchman et al., 1996) and more recently, the ubiquitin ligase, H rdl (Yang et 
al., 2007). Western blot analysis presented here revealed a significant decrease in 
soluble E2(25k) coupled with it’s insolubilisation, denoted by the appearance of a high 
molecular weight smear in R6/2 mice. That E2(25k) would insolubilse and aggregate 
is not wholly unexpected as the mutant huntingtin to which it is postulated to bind to, 
does so. Interestingly, the protein smear is detected clearly from ~140 kDa upwards, 
the size of the first band clearly visible in isopeptide blots which is postulated in this 
study to represent a dimer of N-terminal mutant huntingtin. It seems likely that 
monomers of huntingtin are more readily able to be degraded, but oligomers, possibly 
formed via transglutamination, become progressively more resistant to proteolysis, and 
are therefore more persistent in the cell. This would give rise to the smear from ~140 
kDa upwards seen here. W hilst immunohistochemistry failed to label E2(25k) in 
aggregates in R6/2 mice, it is possibly due to this particular antibodies unsuitability for 
this particular application.
Ubiquitin-like proteins (UBLs), such as SUMO-1, SUMO-2/3, NEDD8 and ubiquilin, 
represent a particularly interesting family of proteins in the context of R6/2 pathology. 
SUMO-1, SUMO-2/3 and NEDD8 have all been shown to act as protein modifiers, 
binding to target proteins in a similar manner to ubiquitin, through a series of E l, E2
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and E3 enzymes (Kerscher et al., 2006). The data presented here shows that in the 
R6/2 model, aggregates are heavily ubiquitinated and contain proteasome components 
and ubiquitin-conjugating enzymes; as UBLs bind similarly to ubiquitin, it seems 
possible their levels or that of their conjugates may be affected, as may localisation. To 
investigate these possibilities, immunohistochemical and immunofluorescent analysis 
was used to demonstrate that Nils, but not DNIs, were strongly immuno-positive for 
SUMO-1 and SUMO-2/3. As mentioned previously, SUMO proteins have been 
implicated in the nuclear transport of proteins, and are attached to target proteins 
through similar mechanisms to ubiquitin. If the enzymatic machinery to ubiquitinate 
proteins is aggregated in R6/2 mice, then it is possible that similar enzymes 
responsible for SUMOlyation are there, too. It seems plausible that in addition to Nils 
acting as sites of proteolysis and ubiquitination, they could also be sites of UBL 
processing and attachment.
Additionally, this study performed western blot analysis using antibodies against 
SUMO-1 and SUMO-2/3 to analyse protein levels and those of their conjugates in 
R6/2 mice. This demonstrated that, in both cases, the soluble pools were absent or 
severely depleted when compared to control animals. Instead, aggregated SUMOylated 
conjugates were detected retained in the well of the stacking gel and as a very high 
molecular weight smear (250 kDa+). Whilst it would be attractive to suggest that it is 
mutant huntingtin that is SUMOylated, this would seem to be unlikely given that, in 
the R6/2, mutant huntingtin is detectable as a smear from ~70 kDa. Interestingly, the 
high molecular weight conjugates of SUMO-1 and SUMO-2/3 (~80 and ~110 kDa,
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respectively) that are detectable in the litter-mate control are absent in R6/2 brains. 
This would seem to indicate that either normal SUMO conjugates aggregate or that the 
depleted soluble pool of free SUMO, due to insoubilsation in aggregates and therefore 
reduced SUMO recycling, reduces conjugation to SUMO’s normal protein targets. 
Another possibility is that these proteins which are SUMOylated in litter mate controls 
are absent in the R6/2. model. However, it seems more likely that a depletion of the 
pool of free SUMO would serve to limit the normal processes of SUMO.
The UBL, ubiquilin, has been suggested to target polyubiquitinated proteins to the 
proteasome (Ko et al., 2004). Whilst not a UBL, the type II AAA (ATPases associated 
with a variety of activities) ATPases, valosin-containing protein (VCP) was also 
investigated here, because amongst its various diverse cellular functions is the 
targeting of polyubiquitinated proteins to the proteasome (W oodman, 2003). 
Therefore, immunohistochemistry and western blot analysis were used to investigate 
VCP and ubiquilins potential involvement in R6/2 neuropathology.
It was unexpected that ubiquilin labelled nuclear but not cytoplasmic aggregates, as 
ubiquilin is known to bind both polyubiquitin chains and 19s proteasome subunits (Ko 
et al., 2004), which this study has shown that DNIs are abundant in. However the 
potential role that ubiquilin plays is somewhat confusing as, whilst it has been shown 
to bind both polyubiquitin chains and the proteasome, in overexpression studies, it’s 
binding to target proteins perversely enhances their stability (Funakoshi et al., 1999; 
Massey et al., 2004). If ubiquilin indeed binds to mutant huntingtin, then whilst it
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might seem like an attractive explanation for it’s persistence in the cell and presence in 
Nils, it would seem odd that DNIs do not label, given their mutant huntingtin and 
ubiquitin content. Despite repeated attempts in this study, VCP antibodies failed to 
label either agggregates, but given it’s aggregation and insolubility, as determined by 
western blot analysis (see below), it seems likely that this represents an unsuitability of 
this antibody for immunohistochemistry.
This study also used western blot analysis to analyse the levels and potential 
insolubility of VCP and ubiquilin. As in the case of SUMO proteins, soluble ubiquilin 
and VCP were greatly reduced and accompanied by a smear on the membrane, 
implying aggregation. It seems likely that the reduced soluble pools of these proteins 
will have implications on the targeting of normal cellular substrates of these proteins to 
the proteasome and it remains possible that this would result in their reduced 
degradation. Furthermore, as VCP has been implicated in cellular functions other than 
degradation such as membrane fusion and DNA replication (Woodman, 2003), a 
reduced soluble pool is likely to have an impact on cellular homeostasis. Interestingly, 
the blot for VCP displays a slightly different smear pattern to that of the UBLs; it 
seems to be split into two densities of smear; initially, the smear begins at ~160 kDa 
and then becomes much more intense from ~230 kDa. These blots bear similarities to 
western blots against the isopeptidase bonds formed by transglutamination. It is 
possible that this represents VCP binding to dimers and trimers of N-terminal 
huntingtin with increasing efficiency. A recent study has shown that the degradation of 
N-terminal huntingtin (with an expanded polyglutamine tract), overexpressed in cells,
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is VCP-dependent (Yang et al., 2007). This would favour the notion that in the R6/2 
model, N-terminal huntingtin is bound to VCP, perhaps in a shuttling role. However, 
the function that VCP is playing here is difficult to assess as, somewhat similarly to 
the case of ubiquilin, a recent paper has demonstrated a role for VCP in both the 
formation and elimination of polyglutamine aggregates (Kobayashi et al., 2007). 
Chaperones, too, represent an interesting family of proteins in the context of 
neurodegenerative diseases of aggregation. Chaperones are known to bind to 
misfolded proteins and either assist in their refolding or present them to the 
proteasome (Esser et al., 2004). In the present study, immunohistochemistry was 
initially employed to identify which chaperones localised to aggregates in the R6/2 
model, the rationale being that these would be relevant to pathology. Out of the 
extensive range of antibodies tested, only members of the Hsp70 family (Hsc70 and 
HDJ-2 / DNAJ), although noticeably, not Hsp70 itself, were shown to localise to Nils 
and, once again, not to DNIs. It was reasoned that as Hsc70 and HDJ-2 / DNAJ 
seemed to be involved in R6/2 neuropathology, western blot analysis of the Hsp70 
family should be undertaken to analyse their protein levels. In agreement with the 
immunohistochemical data neither Hsp40 nor Hsp70 were aggregated or insolubilised 
as determined by the absence of smear on western blots. A somewhat unexpected 
result, given Hsc70’s redistribution to Nils, was that levels of Hsp70 were unaffected 
in the R6/2 model. As Hsc70 is constitutively present in neural tissue, and Hsp70 is 
upregulated in cellular stress (Pavlik et al., 2007; Tytell, 2005), this would imply that 
brains of R6/2 mice do not undergo a typical heat-shock response in response to 
mutant huntingtin expression. However, this present study describes an absence, or
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severe reduction, of Hsp40 in the R6/2 mice and this represents an interesting finding; 
Hsp40, like HDJ-2, is a co-chaperone of Hsc70 (Fink, 1999) and this absence would 
reduce Hsc70’s ability in refolding. However, soluble levels of both Hsc70 and HDJ-2 
were slightly decreased in the R6/2 model, yet both also aggregated and insolublised, 
as detected by a smear. These findings are interesting because they seem to indicate 
that mutant huntingtin expression does not elicit a typical cell stress response in R6/2 
mice brains. Rather, levels of the Hsc70 co-chaperone, Hsp40, are reduced, with no 
elevation of the inducible Hsp70 and both the constitutive protein, Hsc70, and HDJ-2 
aggregate and relocate to Nils but not DNIs. These findings are also consistent with 
another study detailing decreased HDJ-2 levels, and redistribution of Hsc70 and HDJ- 
2 to nuclear, but not neurite aggregates in R6/2 mice (Hay et al., 2004). Another study 
crossed R6/2 mice with those overexpressing Hsp70 and found a modest delaying 
effect on disease phenotype (including aggregate formation), implying that the role 
that Hsp70 plays in R6/2 alleviating neuropathology might be not as significant as 
previously suggested (Hansson et al., 2003). Proteins such as BAG-1 and CHIP are 
known to bind both proteasomes and Hsc70, and can serve to present Hsc70 bound 
proteins to the proteasome for degradation (McDonough et al., 2003). This shift from 
refolding to degradation could be particularly relevant here, given that a non-typical 
cell stress response is displayed. However, as immunostaining and western blotting 
with antibodies raised against both CHIP and BAG-1 failed to label aggregates or 
detect the relevant proteins, this role was unable to be investigated.
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Nils seem to act as focal points for proteasomal proteolysis, similar to the concept of 
clastosomes. The term clastosomes was coined by Lafarga et al., who described them 
as nuclear bodies, enriched in 19s and 20s components, ubiquitin conjugates and UPS 
substrates. Clastosomes are rarely found in normal conditions, but occur when 
proteasomal activity is stimulated and curiously disappear upon proteasomal inhibition 
(Lafarga et al., 2002). Interestingly, inhibition of the proteasome suppresses Nil 
formation in cultured postmitotic neurons (Kim et al., 2004). This study concludes that 
in the R6/2 line, as global proteolysis is increased (chymotrypsin is thought to be the 
most important peptidase activity of the proteasome; see 4.2), and N ils have been 
shown to contain 11s, 19s and 20s components, N ils can be considered to be 
clastosomes. Additionally, this study has shown that Nils also contain POMP, E2(25k) 
and PA200, insinuating that not only are clastosomes areas of intense proteasomal 
activity, but areas of ubiquitination and proteasomal formation / maturation. 
Additionally, this study shows that UBL proteins also recruit and aggregate in these 
clastosomes. This extends the current definition of clastosomes.
Interestingly, another focal point of proteasomal activity has been described, with a 
juxtanuclear localisation, the aggresome (Taylor et al., 2003). Whilst DNIs are also 
cytoplasmic, unlike aggresomes they are found in the neurites of affected neurons. 
Additionally, aggresomes become membrane bound and have been known to fuse with 
lysosomes. There appears to be no such comparison with inclusions in R6/2 mice 
(Professor Stephen W. Davies, UCL, UK, personal communication) and contrary to 
what some studies have suggested, Nils and DNIs are not analogous to aggresomes.
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4.2 Proteolysis in the R6/2 model
The presence of insoluble protein aggregates, shown to contain ubiquitinated expanded 
polyglutamine-containing protein and proteasome components, has led to suggestions 
that the UPS is inhibited in models of polyglutamine expansion disease. Therefore, 
fluorometric assays were used to determine proteolytic activity in the brains of R6/2 
mice.
4.2.1 Altered Proteolysis in the R6/2 model
Initially, fluorometric degradation assays were performed without the use of a specific 
proteasome inhibitor, thereby measuring total (both proteasomal and non-proteasomal) 
proteolysis, and in the presence or absence of SDS. SDS is a known potentiator of the 
proteasome and is thought to activate latent 20s proteasomes by opening the channel 
pore (Shibatani et al., 1995). This study showed that in the absence of SDS, both 
PGPH and chymotrypsin-like activity were increased, whilst trypsin-like activity was 
decreased. That chymotrypsin-like activity is significantly increased in the presence of 
SDS implies that additional to the proteasomes expressing elevated chymotrypsin-like 
peptidase activity in the R6/2 model are proteasomes present in a latent state. This 
represents an interesting finding because it implies that there are additional functional
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but inactivated proteasomes, when compared to litter-mate controls, that could be 
harnessed to increase cellular degradation, which would have implications for future 
therapeutic approaches. Additionally, that the decrease in trypsin-like activity is 
abolished in the presence of SDS could mean that there are proteasomes capable of 
normal trypsin-like activity. It has been postulated that expanded polyglutamine 
containing proteins could become physically stuck in the 20s pore, thus causing 
proteasomal inhibition. It is plausible that, in this scenario, mutant huntingtin could 
block the active sites relevant to trypsin-like activity and leave the others relatively 
unaffected. SDS could open the channel enough to “free” the 20s pore from mutant 
huntingtin, which would have the effect of normalising the trypsin-like activity as 
seen. However, as these were preliminary experiments analysing total peptidase 
activity (proteasomal and non-proteasomal) and were intended to serve as a starting 
point to gauge any gross changes prior to more specific experiments aimed at 
measuring proteasomal activity, further proteolytic assays were performed in the 
absence of SDS in order to represent a more physiological assessment of proteolysis.
Whilst there have been studies investigating proteolysis in cells transfected with 
mutant huntingtin / polyglutamine, the in vivo studies have not always reflected 
accurate measures of proteasomal activity. Diaz-Hernandez et al., reported increases in 
both chymotrypsin and trypsin-like proteasomal activities in HD94 mice (Diaz- 
Hernandez et al., 2003). However, this study used lactacystin, which has been shown 
to be a non-specific inhibitor of the proteasome (Rodgers et al., 2003; Vigouroux et 
al., 2003a; Vigouroux et al., 2003b), and Triton X-100, which has been shown to
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inhibit the proteasome (Arribas et al., 1990). Other detergents, such as SDS, have been 
shown to increase the activity of the proteasome by opening the pore (Shibatani et al., 
1995). Consequently, detergents should not be used in assays to ascertain the state of 
proteasomal activity in neurodegenerative disease, as by increasing or inhibiting the 
proteasome, they do not reflect a physiological representation of peptidase activity. 
Another study has attempted to study proteasomal activity in HD brains and skin 
fibroblasts (Seo et al., 2004), finding both PGPH and chymotrypsin-like activity to be 
decreased. However, this study measured PGPH and chymotrypsin-like and not 
trypsin-like activity and did so in without the use of a specific proteasome inhibitor, 
thereby also measuring protease activity. In the present study, to differentiate between 
proteasomal and non-proteasomal proteolysis, peptidase activity was measured in the 
presence and absence of epoxomicin. Epoxomicin is the most specific proteasomal 
inhibitor currently known and a concentration of 20pM , is sufficient to inhibit 
chymotrypsin-like, trypsin-like and PGPH-like proteolytic activities of the 20s 
proteasome (Dr. Alexei Kisselev, Dartmouth M edical School, USA, personal 
communication and (Sin et al., 1999). Therefore, this represents the first accurate 
study of both proteasomal and non-proteasomal chymotrypsin, trypsin and PGPH-like 
peptidase activity in a murine model of HD.
This study shows that in the R6/2 model, the 20s proteasome is not inhibited, but 
exhibits a differential proteolytic profile when compared to litter mate controls, with 
some activities increased (PGPH and chymotrypsin-like) and one decreased (trypsin­
like). Furthermore it shows that chymotrypsin-like, trypsin-like and PGPH non-
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proteasomal peptidase activities are all decreased. However, which specific non- 
proteasomal protease contributes to the cleavage of these fluorogenic substrates is 
unclear at present. One study has described the presence of a novel 105 kDa protease 
in brain that exhibits both chymotrypsin-like and trypsin-like activity (Vigouroux et 
al., 2003b). This is likely to be one of many cellular proteases that contributes to 
cleavage of fluorogenic compounds in these types of proteasomal activity assays. It is 
known that several proteases function and reside within the highly acidic, membrane- 
bound environment of the lysosome and, because the fluorometric assays were 
conducted at a higher pH, it is unlikely that lysosomal proteases would, or indeed 
could, contribute to the measured non-proteasomal peptidase activity in this study. 
Whilst this thesis is predominantly concerned with the contribution of the proteasome 
to cellular proteolysis, other non-proteasomal proteases play a significant part in the 
degradation of the measured fluorometric substrates. For example, this study shows 
that in control animals, nearly 60% of all measured trypsin-like activity is via non- 
proteasomal proteases, compared to just 25% in R6/2 animals. In fact, as all of these 
non-proteasomal activities are greatly reduced in the R6/2, and two activities (PGPH 
and chymotrypsin-like) are increased in proteasomes, it implies that the cell becomes 
much more dependent on the proteasome to degrade proteins. To the authors 
knowledge, this apparent shift in favour of proteasomal proteolysis in the R6/2 has not 
been noted before in the literature.
There are certain problems associated with interpreting the data from these 
fluorometric assays. Firstly, unlike global proteasomal changes (ie. increases or
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decreases in all of the peptidase activities), the data from the R6/2 model shows that 
some activities are increased, whilst one, the trypsin-like activity, is decreased. The 
actual effects on protein degradation are therefore very difficult to estimate. 
Chymotrypsin-like activity has often been reported to be the most important of the 
proteasomes peptidase activities and is seen to be increased dramtically in the R6/2 
model alongside increases in PGPH activity, so global proteasomal proteolysis might 
be seen to be increased. This problem is compounded by the fact that all of the non- 
proteasomal proteases activities are decreased in R6/2 mice, and, as mentioned before, 
because they are responsible for a significant proportion of proteolytic activity, it is 
difficult to take into account when considering total protein degradation. Secondly, it 
should be bourne in mind that this study demonstrates differential proteolysis in whole 
brain samples in R6/2 mice as opposed to measuring the proteasomal activity in 
specific brain regions or even cellular compartments. A recent study shows regional 
differences in proteasomal activity in the brain (Zeng et al., 2005), highlighting the fact 
that there are different heterogenous populations of proteasomes in different brain 
areas anyway. It is possible, and perhaps even likely, that specific regions of the brain 
are more dramatically affected than others; measuring proteolysis in whole brain 
homogenates is likely to mask some of those differences and therefore makes the 
changes seen here that much more striking. Additionally, it seems likely that there are 
compartmental differences in the proteolytic profiles of, for example, nuclear versus 
cytoplasmic proteasomes. This is highlighted by the differential recruitm ent of 
proteasome components to N ils and DNIs and could potentially be a factor in why
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cytoplasmic and nuclear inclusions appear to be made up of different fragments of 
mutant huntingtin (Lunkes et al., 2002).
Three very recent studies, published during the writing of this thesis, are pertinent and 
should be mentioned here. The first study employed a novel method to analyse 
proteasome activity using mass-spectrometry to measure polyubiquitin chains, which 
the authors concluded was a valid method to measure proteasome impairment, and 
found that in both R6/2 and HD brains, global proteasomal function was decreased 
(Bennett et al., 2007). However, this does not mean decreases in overall proteasomal 
proteolysis, ie. decrease in protein degradation (one of the problems with interpreting 
the data from fluorometric methods). The authors essentially use a comparison of free 
ubiquitin to polyubiquitin chains with the implication being that increased “build up” 
of polyubiquitinated conjugates represents UPS dysfunction. Whilst this is a novel and 
useful system to measure general UPS function it is plausible to imagine several 
scenarios which would caution against using this method as a measure of proteasomal 
function: increased rates of ubiquitination could cause a build up of polyubiquinated 
conjugates; perturbations of polyubiquitin shuttling proteins to the proteasome would 
increase conjugates; polyubiquitinated proteins could be insoluble (as is the case with 
many neurodegenerative proteins), aggregate and be resistant to degradation and 
therefore persistent in the cell regardless of proteasome function etc. So whilst the 
authors say that the UPS is dysfunctional to a greater extent in the R6/2 model (this 
present study confirms this and sees many changes to various elements of the UPS) 
and HD patients than previously thought, at which level this first occurs is unclear.
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Another study of interest here used both fluorometric substrates and a series of 
reporters to analyse UPS function and proteasomal proteolysis in a striatal cell model 
of HD (Hunter et al., 2007). This study used a comprehensive methodology to 
investigate UPS function and activity and also found that the proteasome was 
differentially regulated. H ow ever, the authors discovered that PGPH and 
chymotrypsin-like activities were slightly decreased, whilst trypsin-like activity was 
increased; the opposite pattern of what is seen in this present study. There could be 
several reasons for this discrepancy. Firstly, the present study was performed used 
whole brain homogenates, whilst the study by Hunter et al. specifically used a striatal 
cell line. It is expected that neural cell type will affect proteasomal profile and the use 
of whole brain homogenates masks cell-specific differences in proteasome activity. It 
would be ideal to compare the proteasomal profile of several cell types derived from 
HD and control brains. Secondly, the model from which these cells are derived differ 
in their neuropathology from R6/2 mice. It is possible that the proteolytic profiles are 
slightly different between these models (as in the immunoproteasome involvement in 
HD94 mice) and as mentioned before, caution should be exercised extrapolating data 
from one model to another. However, the present study, like the work of Hunter et al. 
interestingly shows differential proteolytic profiles as a result o f polyglutamine 
expansion. The third interesting recent study measured chymotrypsin-like activity in 
R6/2 mice and, in agreement with the present study, found increases when compared 
to control animals (Bett et al., 2006). Additionally, whilst Bett et al. reported smaller 
increases in chymotrypsin-like activity than those reported in this study, they also 
noted that this increase was not significant at 8 weeks of age, only becoming apparent
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by 13 weeks. This would imply that changes in proteasomal activity occur fairly late in 
the pathology of R6/2 mice and are not a primary event. All the mice used in the 
present study are 13 weeks old; it would be of interest to know at what stage more 
sensitive assay conditions would note a change in proteolysis. However, it should be 
noted that Bett et al. only measured chymotrypsin-like activity and it is wholly 
possible that early changes can be detected in PGPH or trypsin-like activity.
The UPS is a fundamental mechanism for controlled protein degradation in all cells 
and is central to many different cellular processes. As proteasomes in the R6/2 model 
exhibit very different proteolytic profiles when compared to litter mate controls, it is 
probable that some of the pathological features of polyglutamine expansion diseases 
could be either exacerbated or come as a direct consequence of altered proteolysis. For 
example, the proteasome is involved in the regulation of transcription factors (Lipford 
et al., 2003) and transcriptional dysregulation has been suggested as a mechanism of 
neurodegeneration in polyglutamine expansion diseases (Helmlinger et al., 2006; 
Thomas, 2006). It is possible that the described changes in gene regulation are a result 
of altered proteolysis, and therefore transcription factor regulation. Additionally, 
amongst the many described functions of the UPS, a role in mediating morphological 
changes in dendritic spines has been proposed, whereby UPS-dependent degradation 
of certain proteins (eg. spine-associated Rap GTPase activating protein (SPAR)) result 
in dissipation of dendritic spines (Yi et al., 2005). Indeed, morphological changes have 
been reported in dendrites and their spines in HD brains (Ferrante et al., 1991; 
Graveland et al., 1985). Furthermore, dendritic retraction and spine dysmorphia is a
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pathological feature of striatal, cortical and hippocampal neurons in the R6/2 model 
(Aysha Raza, UCL, personal communication and (Klapstein et al., 2001). It seems 
plausible to suggest that the altered proteasomal activation seen in R6/2 mice brains 
could be a contributory or, indeed, causative factor in dendritic dysmorphia. Taking 
this idea a step further, it is known that R6/2 brains weigh considerably less than their 
age-matched litter mate controls (Davies et al., 1997) and that this may be due to 
neuronal shrinkage and not cell death (Aysha Raza, UCL, personal communication). 
Perhaps, on a larger scale, the altered peptidase activity displayed by the proteasome 
could result in increased degradation of cellular proteins and cell shrinkage. It is 
already known that muscle cachexia, a feature of cancer and AIDS patients, can occur 
through a proteasome dependent mechanism, and that attempts have been made to 
inhibit muscle breakdown through inhibition of the proteasome (Acharyya et al., 
2007).
4.2.2 Regulation of the proteasome in the R6/2 model
There are several possible factors that could contribute towards the altered proteasomal 
proteolysis seen in the R6/2 mice: 1) Altered levels of the 20s core particle, 2) changes 
in maturation of the proteasome, 3) changes in the subunit composition of the 20s 
proteasome or 4) changes in one (or more) regulatory particles of the 20s proteasome.
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As the various peptidase activities o f the proteasome can be attributed to specific 
subunits of the proteasome, initially western blot analysis was used to determine levels 
or potential changes to these 20s P-subunits in addition to 20s a-subunits in the R6/2 
20s proteasome. It should be noted here that there are inherent problems that can 
present when comparing proteins levels in the R6/2 model versus litter-mate controls. 
Whilst soluble protein levels may be readily compared, it is difficult to interpret levels 
of aggregated protein when coupled with decreases in soluble protein, as higher 
molecular weight proteins (including aggregates) are known to transfer less efficiently 
to nitrocellulose membranes. Having stated that, in the case of 20s a-subunits in the 
R6/2 model compared to litter-mate controls, there is a clear increase in soluble 20s a -  
subunits in addition to several higher molecular weight species and aggregated protein. 
As the 20sa  antibody is raised against and recognises many 20s proteasome a -  
subunits, it can be seen as a useful tool for comparing levels of the 20s proteasome per 
se. Whilst increases in protein levels cannot be confirmed from western blot analysis 
of 20s P-subunits (due to decreases in soluble protein, coupled with higher molecular 
weight bands and aggregated protein) it seems probable that the entire 20s proteasome 
is upregulated, and not just the a-subunits. An implication of this is that the increases 
in PGPH-like and chymotrypsin-like peptidase activities could be simply due to 
increases in levels of 19s (see below) and 20s core particles. However, as altered levels 
of PI31K (see below) were also noted, the increased levels of 20s core particles in the 
R6/2 model is more likely to represent a contributory factor to increased PGPH and 
chymotrypsin-like activities.
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In the cases of p i and (35 subunits, the soluble form of the proteins was absent and 
greatly reduced, respectively. As mentioned previously with regards to comparing 
soluble and insoluble proteins, it is impossible to infer whether or not the protein levels 
of these subunits is altered, but it is clear that immunodetection of both subunits was 
almost exclusively in insoluble smears. It has been argued that sequestration of 
proteins into polyglutamine aggregates could reduce or even nullify their function, 
thus contributing to neurological dysfunction (Donaldson et al., 2003). For example, in 
a cell culture model of SCA-3, it has been shown that CREB-binding protein (CBP) 
relocalises to aggregates, resulting in reduced levels of soluble CBP, despite an 
increase seen in CBP mRNA, and that rescue of cellular toxicity could be achieved by 
overexpression of CBP (McCampbell et al., 2000). Data from the various experimental 
approaches can be used to answer important questions regarding the functionality of 
proteins that have been retarded in aggregates. Both immunohistochemical and 
western blot data show that nearly all of the detected 20s pj and p5 subunits in R6/2 
brains is present within insoluble aggregates (retained at the top of the gel in westen 
blots or localised to aggregates in immunohistochemistry analysis) and that soluble 
forms of the protein are near absent. However, data from the fluorometric assays show 
elevation of the corresponding chym otrypsin-like and PGPH-like proteasomal 
activities (see 4.2). Importantly, this implies that whilst these 20s proteasomal subunits 
may become insolubilised in aggregates, they are still functionally active. This is 
somewhat surprising as it is expected that aggregation of certain 20s proteasome 
subunits would physically interfere with subunit-subunit interactions and result in 
them not being able to form whole functional 20s proteasomes. It could still be argued,
132
however, that sequestration of 20s proteasom es into aggregates could still lead to 
cellular dysfunction, as the proteasome is not distributed throughout the neuron in a 
normal manner and could be unable to perform degradative duties in compartments 
other than aggregates.
The case of the 20s p2 subunit is slightly different; this subunit corresponds to the 
trypsin-like pesidase activities of the proteasome, which were found to be decreased in 
the R6/2 model. 20s P-subunits are initially translated as propeptides that are 
autolytically cleaved to form mature subunits. For example, 20s p6-subunits exist as 
free propeptides (25 kDa) within the cell, and are cleaved into mature polypeptides (23 
kDa) concomitant with their incorporation into intermediate or mature proteasomes 
(Rodriguez-Vilarino et al., 2000). Western blot analysis using antibodies raised against 
20s p2 subunits revealed the presence of two low molecular weight bands in control 
samples at ~25 and 28 kDa, likely to correspond to precursor and mature forms of the 
protein. However, in the R6/2 samples, only the propeptide is detected and the mature 
polypeptide is absent. This implies that the 20s p2 subunit may not be normally 
autolytically cleaved in the R6/2 model. It is possible that there is incomplete 
maturation of this subunit, and this would help to explain the decrease seen in trypsin­
like activity. However, a potential problem with this interpretation is whether or not 
complete 20s proteasomes are able to form in the absence of a mature p2-subunit and 
utilise a precursor in i t’s formation. Data regarding the assembly of mammalian 
proteasomes is currently not as well documented as that for yeast proteasomes, and, as 
such, there are several conflicting models describing formation and the potential
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presence of intermediate proteasom es with unprocessed |3-subunits (Rodriguez- 
Vilarino et al., 2000). It is wholly possible that in R6/2 brains, immature P2-subunits 
are incorporated into interm ediate proteasomes that exhibit functional peptidase 
activity. In support of this idea is that intermediate proteasomes have been described 
with functional catalytic properties (Dahlmann et al., 2000).
To explore the possibility of whether the altered proteasomal proteolytic profile seen 
in R6/2 mice was due to changes in proteasomal regulation, the protein levels of 
known 20s regulators were analysed by western blot. Perhaps the best known and 
comprehensively described regulators of the 20s proteasome are the 11s and 19s 
regulatory complexes. However, in this study, western blot analysis failed to detect 
any differences in the levels of soluble 11s a ,  (3 or y subunits between R6/2 and litter 
mate controls and additionally, unlike that of the 20s subunits tested, higher molecular 
w eigh t sp ec ie s  o r in so lu b ilised  p ro te in  w ere undetec tab le . As the 
immunohistochemical data (discussed in 4.1.2) showed that a small proportion of Nils 
were immunopositive for l i s a  subunits (and not l i s p  or y), it is unlikely that any of 
the 11s subunits play a significant role in R6/2 pathology or altered proteolytic profile, 
and that the 1 ls a  subunits presence in a few Nils is more likely to be due to its affinity 
for the 20s proteasome, concentrated in Nils. As the l i s a  regulator is known to alter 
the proteolyic profile (Li et al., 2001a; Li et al., 2001b) of the 20s proteasome, it 
would be expected that the 20s proteasomes cleavage pattern will be different in the 
nuclei containing 11s immunopositive aggregates versus those containing 11s
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immunonegative aggregates, although this is only a small proportion of Nil containing 
nuclei.
The 19s complex is thought to activate the proteasome by recognizing ubiquitinated 
substrates, then unfolding and translocating them into the lumen of the 20s core. 
Without 19s regulatory complexes, or similar (eg. PA200), 20s proteasomes would 
effectively not be able to efficiently degrade ubiquitinated substrates. Western blotting 
was used to analyse the levels of 19s Rpn2 subunits and revealed an increase in protein 
levels. Whilst it is recognised that this antibody recognises only one subunit of the 19s 
regulatory complex, as two of the other tested 19s antibodies failed to detect any 
protein via western blotting in either the R6/2 or litter mate controls, the Rpn2 
antibody was relied upon to give an indication of the protein levels of the whole 19s 
regulatory complex. As the immunohistochemical data revealed that both DNIs and 
Nils were strongly immunopositive for antibodies raised against various 19s subunits, 
and as 20s antibodies labelled N ils but not DNIs, it could be expected that an 
increased level of 19s complexes would increase the proteasomal degradation in Nils. 
As both 20s and 19s complexes seem to be increased in the R6/2 compared to litter 
mate controls, it is probable that the increases seen in PGPH-like and chymotrypsin- 
like peptidase activities are partially due to elevated levels of 19s-20s complexes.
Immunoproteasomes represent another subtype of proteasome with altered proteolytic 
profiles and, particularly pertinent to this study, when compared to constitutive 
proteasomes, depress chymotrypsin-like and PGPH activity whilst enhancing trypsin­
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like activity (Dahlmann et al., 2000). However, in this study western blot analysis of 
the levels of the y-interferon inducible subunits, LMP2, MECL-1 and LMP7 failed to 
reveal any differences between R6/2 or litter-mate controls. Furthermore, that western 
blotting failed to show any high m olecular weight species or aggregated protein 
smears coupled with their absence from either nuclear or cytoplasmic aggregates in 
immunohistochemical studies, clearly demonstrates that immunoproteasomes are not 
involved in the pathology or differential proteolysis seen in R6/2 mice. This is in 
contrast to the work of D iaz-H ernandez et al., who detec ted  increased  
immunoproteasome subunits LM P2 and LMP7 in HD94 brains. Whilst the authors 
suggest a role in HD neurodegeneration for immunoproteasomes, the significance of 
this role is questionable given that recruitment of LMP2 only occurs in a very small 
population (5%) of ubiquitin-positive cortical aggregates. A further difference to what 
this present study describes in R6/2 mice, as mentioned before, was that the authors 
reported increases in trypsin and chymotrypsin-like activities in the HD94 model 
(Diaz-Hernandez et al., 2003). Taken together, this shows that the proteasome 
expresses a different proteolytic profile and regulation in the R6/2 mouse when 
compared to the HD94 model and reiterates the differences that exist between models 
of polyglutamine expansion diseases and the pitfalls o f extrapolating data from one 
model to another.
Two further known regulators of proteasomes were examined, PA200 and PI31K. 
Western blot analysis of PA200, a proteasome activator that is known to increase 
proteolysis by opening the 20s pore (Ortega et al., 2005), revealed that soluble species
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of PA200 are absent in the R6/2 model and instead form smears on western blots and 
remain as aggregated in the stacking gel. Whilst this demonstrates redistribution of this 
protein to, and insolubilisation with, aggregates, as described before, it is impossible to 
infer any difference in protein levels between the samples. This, again, raises the 
question of why expression of mutant huntingtin protein would induce the selective 
aggregation and insolubilisation of seemingly unconnected proteins. For example, it 
seems odd that 19s, 11s and immunoproteasome subunits do not seem to insolubilise, 
whilst 20s subunits and PA200, a protein that binds 20s core particle in a similar 
manner to 19s complexes, do. However, in the case of PI31K, there is a marked 
decrease in protein levels in R6/2 mice. PI31 is a 31 kDa protein that competes for 20s 
binding with 11 sap  and PA200 and is thought to affect proteasomal activity. Whilst 
not a lot is currently known about PI31K, it has been shown that PI31 inhibits 
chymotrypsin-like and PGPH-like activity, whilst sparing trypsin -like activity (Zaiss 
et al., 1999; Zaiss et al., 2002). It seems that the decrease seen in PI31 levels in R6/2 
brains, and hence lack of inhibition, could partially account for increased 
chymotrypsin- and PGPH-like peptidase activity of the proteasome.
The altered proteolytic profile seen in R6/2 mice is due to complex changes in 
regulation and protein levels of various proteasomal components. In summation, it 
seems probable that increased chymotrypsin-like and PGPH peptidase activities are 
likely to be due to a combination of elevated 19s and 20s levels and a decrease in the 
inhibitory protein, PI31K. The depression of trypsin-like activities clearly requires 
further examination, but the initial findings presented here potentially indicate
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immaturity and incomplete cleavage of 20s p2 subunits could be responsible for 
changes in this peptidase activity.
4.3 Future studies
Several areas of future study are clearly required to follow up the questions that this 
work raises. Firstly, the altered proteolytic profile of R6/2 proteasomes needs to be 
addressed. A previous study has identified different proteasomes subtypes using 
negative staining electron microscopy (C ascio et al., 2002). This technique would 
allow for ratios of proteasome subtypes, for example 19s-20s-19s : l ls -2 0 s - l ls  : 
uncapped 20s, to be measured between R6/2 and control samples. Furthermore, 
com bining this approach with a cellular fractionation method (nuclear and 
cytoplasm ic) and further fluorom etric assays would provide insights into the 
differences between cytoplasmic and nuclear proteasomes and how they could 
contribute to differing cytoplasmic and nuclear aggregates, an area particularly 
highlighted by this present study. Indeed, a recent study has shown that there is 
differential regulation of nuclear and synaptic proteasomes in Aplysia (Upadhya et al., 
2006).
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Secondly, a combination of w estern  blotting, trypsin gel-digests and mass- 
spectrometry could be employed to further explore the nature of the post-translational 
modifications of 20s p2 subunits and of the high molecular weight species detected in 
the 20sa blots. This approach could also be used to clarify whether there are any 
further post-translational modifications of the 20s proteasome that could account for 
the altered proteolytic profile seen in R6/2 mice. For example, a recent paper described 
the profound effect of phosphorylation (via PKA) of specific 20s subunits, including 
P2, in altering peptidase activities of murine cardiac proteasomes (Zong et al., 2006).
Several other questions remain: W hat other proteins regulate the proteolytic profile of 
20s proteasomes and are they involved in R6/2 neuropathology? What proteases are 
responsible for the decreased non-proteasomal proteolysis in R6/2 mice? W hat is the 
effect of decreased UBL free pools on the cell? Is deubiquitination affected in the R6/2 
model? At what stage does proteolysis first become affected in R6/2 mice?
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Conclusions
The work presented here strongly implicates the UPS in the neuropathology of the 
Huntington’s disease mouse model, the R6/2. Both N ils and DNIs are typically 
granular, amorphous structures unlikely to be primarily composed of fibrils formed by 
P-pleated sheets. Instead ubiquitinated mutant huntingtin protein is likely to form 
oligomers and aggregate through the process of transglutamination. N ils and DNIs 
were shown to differentially recruit proteins involved in degradation and refolding. 
N ils are rich in many proteasom e com ponents, UBLs, and proteins involed in 
ubiquitination and proteasome biogenesis, further developing the concept of the 
clastosome. DNIs appear to include far fewer proteins than N ils and this might be 
important when considering their respective effects on the cell. Fundamentally, the 
proteasome is not inhibited in this model, rather it is differentially regulated, whilst the 
activity of many cellular non-proteasomal proteases is decreased. Global increases in 
20s and 19s proteasome levels and decreases in the levels of the proteasomal inhibitor, 
PI31K, are both likely to be contributory factors involved in increased PGPH and 
chymotrypsin-like peptidase activities, whilst decreased trypsin-like activity may be as 
a result of incomplete maturation of the 20s proteasome.
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Appendix 2: Representative images dem onstrating the scoring scale used for strength 
of immunohistochemical staining. = antibody unable to label aggregates (A) * = 
immunostaining o f aggregates rare or infrequent (B); ** = moderate quantity o f aggregates 
immunopositive (C); *** = high staining frequency (equivalent to that produced by ubiquitin 
or Huntingtin antibodies (D). Scale bar=20pin.
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